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ABSTRACT 
Genomic DNA must exist in a particular chromatin configuration and 
modification of this structure is essential for the correct control of gene 
expression. There are several human genetic disorders that are caused by 
misregulation of epigenetic gene control. Facioscapulohumeral muscular 
dystrophy (FSHD) is a disease that may be caused by alterations in chromatin 
structure. FSHD is the third most common form of muscular dystrophy. The 
majority of FSHD cases show contraction of the D4Z4 repeats on the 4q35 
chromosome (FSHD1). However, a small number of FSHD cases show no 
contraction at this region (FSHD2), but share epigenetic changes at the D4Z4 
region with the FSHD1 patients. In 2009, Zeng et al. reported a specific loss of 
H3K9me3 histone modification at the D4Z4 repeats in FSHD patients. 
The main focus of this study was to verify the published data by Zeng et al 
(2009) and further investigate the histone modification changes at the D4Z4 
array. Chromatin immunoprecipitation (ChIP) coupled with real-time 
quantitative PCR (qPCR) was employed to investigate the histone 
modifications within the D4Z4 array. 
The results obtained were in agreement with the previously published data on 
the reduction of H3K9me3 histone modification at the D4Z4 repeats in FSHD 
patients. However, contradictory to the previous data, the reduction of this 
histone modification was also observed on other genomic regions. A global 
reduction of H3K27me3 was also observed in FSHD patients. 
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1. Introduction 
 
1.1 Concept of Epigenetics 
The term epigenetics has been defined as heritable changes in gene expression 
that occur without a change in DNA sequence (Wolffe et al. 1999).  
This is made possible due to epigenetic modification of the genome, which 
enables different gene regulation and expression in different cell types. 
Somatic cells in a multicellular organism all have essentially identical 
genomes, but each of these cells has a distinct structure and function.  Gene 
regulation has two components, labile regulation and epigenetic regulation. 
Labile regulation in controlled by fluctuation of nuclear proteins concentration, 
covalent modifications and subunit associations of transcriptional activators 
and repressors. The chromatin structure, with its covalent modifications and 
stable protein associations, provides epigenetic regulation and constitutes the 
epigenotype. These two components of gene regulation act very closely and in 
harmony with each other and hence there is not always a clear boundary 
between their actions (Jiang et al. 2004). 
1.1.1 Chromatin structure 
An epigenotype is established primarily through the folding of DNA into 
chromatin and the architecture of the chromatin within the nucleus. In 
eukaryotic organisms, DNA is packaged with histones within the nucleus of 
the cell into either euchromatin or heterochromatin regions. Euchromatin is an 
expanded open structure that consists of mostly actively transcribed genes, 
 14 
while heterochromatin is a contracted and closed structure, which represents 
transcriptionally inactive conditions. Identification of these two types of 
chromatin led to the hypothesis that differences in chromatin structure might be 
associated with tissue-specific or temporal differences in gene expression 
(reviewed by Jiang et al. 2004). 
A first level of compaction of DNA (5-10x) is achieved by organization into 
nucleosomes. Approximately 146bp of DNA is wound twice around an 
octamer of core histones consisting of two of each of the four histones H2A, 
H2B, H3, and H4 (Figure 1.1). Adjacent nucleosomes are connected by a 
segment of linker DNA to form a 30-nm fiber, and the addition of histone H1 
to each nucleosome lends stability to and facilitates the formation of further 
higher-order structures (Jiang et al. 2004).  
 
Figure 1.1 Structural organisation of nucleosome and chromatin 
packaging 
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1.1.2 Histone modifications 
Amino acid residues within the histones, particularly the amino-terminal ends 
of the histone proteins, are subject to a wide range of different post-
translational covalent modifications. There are at least eight distinct types of 
modifications found on histones which are shown in Table 1 (Kouzarides 
2007). Histone modifications affect the histone-histone and histone-DNA 
interactions, thus affecting the overall structure of the nucleosome and how it 
interacts with the DNA. As a consequence histone modifications can effect the 
chromosome structure and gene expression. The entirety of these chemical 
PRGLILFDWLRQVLVFDOOHGWKH³KLVWRQHFRGH´ZKLFKSURYLGHV the mammalian cell 
with another layer of gene regulation. The timing of the appearance of a 
modification depends on the signaling conditions within the cell (Kouzarides 
2007).  
The use of modification-specific antibodies in chromatin immunoprecipitation 
(ChIP) (section 1.4) has enabled study of histone modifications at particular 
sites such as promoters and enhancers (Barski et al. 2007; He et al. 2010). 
Monitoring of the global incidence of histone modifications is also possible by 
coupling of ChIP with DNA-microarray analysis (ChIP-CHIP) (De Gobbi et al. 
2007; Pauler et al. 2009) or deep sequencing (ChIP-seq) (Pauler et al. 2009). 
Certain gene regulatory features have come to light regarding the composition 
and enrichment of certain histone modifications on various regions of the 
genome, which are reviewed in Kouzarides (2007). 
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Table 1.1 Overview of different histone modifications and the functions 
that have been associated with them.  
Table from Kouzarides (2007) 
 
Amongst all the known modifications, acetylation has the most potential to 
unfold chromatin since it neutralises the basic charge of the lysine. In 
agreement with this, in general, euchromatin regions of the genome are marked 
by high levels of acetylation (Kouzarides 2007). High levels of acetylation are 
detected in promoter regions of active genes (Bernstein et al. 2005; Kim et al. 
2005; Roh et al. 2005). Histone acetylation has also been observed in 
intergenic regions, where it has been correlated with functional enhancers in 
various cell types (Heintzman et al. 2007; Roh et al. 2007). Histone acetylation 
is catalysed by Histone acetyltransferases (HATs). HATs are divided into three 
main families, GNAT, MYST and CBP/p300 (Sterner et al. 2000). In general 
these enzymes can acetylate more than one lysine but some limited specificity 
has been observed. For example, HAT1 can only acetylate lysine 5 and lysine 
12 of histone H4 (Kouzarides 2007). Acetylation is reversed by histone 
deacetylase (HDAC) enzymes. Deacetylation correlates with chromatin 
condensation and gene transcription repression. HDACs are involved in 
multiple signaling pathways and they are present in a number of repressive 
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chromatin complexes. Generally, these enzymes do not show any specificity 
towards a particular acetyl group (Kouzarides 2007). 
In comparison with all the various histone modifications, methylations at lysine 
and arginine residues are relatively stable and are therefore considered 
potential markers for carrying epigenetic information through the cell cycle. 
ChIP-Seq analysis (ChIP data analysed by direct sequencing) on human HeLa 
cells and T-cells has revealed that the three methylation states of lysine 4 of H3 
(H3K4) were elevated surrounding the transcription start sites (TSSs). These 
signals move from mono- to di- to trimethylated H3K4 while approaching the 
TSSs (Barski et al. 2007; Heintzman et al. 2007). Methylation of H3K27 had 
previously been correlated with gene repression (Lee et al. 2006; Roh et al. 
2006). The ChIP-seq analysis by Barski et. al. (2007) confirmed the correlation 
between di- and trimethylation of H3K27 with silence promoters. In contrast, 
H3K27me1 signals were higher at active promoters, particularly downstream 
of the TSSs (Barski et al. 2007). Methylation of H3K9 is often associated with 
heterochromatin formation and gene silencing and the data from Barski et.al. 
(2007) confirmed the presence of H3K9me2 and H3K9me3 in silenced 
promoters. However, some previous studies have reported the enrichment of 
H3K9me3 in some active promoters and actively transcribed regions (Vakoc et 
al. 2005; Squazzo et al. 2006). 
The enzymes involved in histone methylation are the most specific and have 
been implicated in playing critical roles in development and pathological 
processes (Barski et al. 2007; Kouzarides 2007). These enzymes often work 
alongside other factors such as DNA methyltransferases or DNA polymerase II 
(Cedar et al. 2009).  For instance, SUV39H1 and SUV39H2 are two of the 
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enzymes responsible for trimethylation of H3K9. By recruiting DNMT3A and 
DNMT3B to methylated CpG sites, SUV39H1 and SUV39H2 are responsible 
for heterochromatinisation of satellite repeats (Fuks et al. 2003; Lehnertz et al. 
2003). 
1.1.3 DNA methylation 
In mammals, DNA methylation is found predominantly at the carbon-5 
position of about 80% of all cytosines that are part of symmetrical CpG 
dinucleotides. Most 5-methylcytosines lie within retrotransposons, endogenous 
retroviruses, or repetitive sequences (Bestor et al. 1996; Yoder et al. 1996). 
Consequently it is thought that methylation may have evolved as a host defense 
mechanism to prevent the mobilization of these elements and to reduce the 
occurrence of chromosomal rearrangements. It is now clear that DNA 
methylation has essential roles in mammalian development and plays a crucial 
role in variety of different biological processes such as genomic imprinting 
(Ferguson-Smith et al. 2001) and X-inactivation (Lee et al. 1997). 
Unmethylated CpG dinucleotides are found mainly in short CpG-rich sequence 
domains known as CpG islands that are in the vicinity of gene promoters (Ng 
et al. 1999). Unmethylated CpG islands are normally found in transcriptionally 
active genes, whereas developmental and tissue-specific genes mostly appear 
to be methylated and silenced in different tissues (Kundu et al. 1999; Bird 
2002).  
Mouse embryological studies have shown that the methylation pattern is erased 
in early embryo and is re-established at approximately the time of implantation 
(Monk et al. 1987; Kafri et al. 1992). Methylation during development is 
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established by two counteracting mechanisms: a wave of indiscriminate de 
novo methylation (Okano et al. 1999) and a mechanism that ensures the CpG 
island remain unmethylated. The precise details of how CpG islands are 
protected from methylation are not completely understood. Early studies 
suggested that the protection might be directed by recognition of common cis-
acting sequences located in CpG islands (Macleod et al. 1994; Siegfried et al. 
1999) and mediated by active demethylation (Frank et al. 1991). Recent studies 
in mice suggest that histone modification might be accountable for the 
establishment of the basic DNA methylation profile during early mammalian 
development (Ooi et al. 2007). Under this model, the pattern of methylation of 
H3K4 across the genome might be formed in the embryo before de novo DNA 
methylation. DNA regions that are packaged with nucleosomes containing 
unmethylated H3K4 are subject to de novo DNA methylation while regions 
packaged with nucleosomes containing methylated H3K4 are protected from 
de novo DNA methylation (Ooi et al. 2007). H3K4 methylation might be 
directed by sequence-directed binding of RNA polymerase II, which was found 
to recruit specific H3K4 methyltransferases (Guenther et al. 2007). As RNA 
polymerase II is bound mostly to CpG islands in the early embryo, these 
regions are marked by methylated H3K4 and are protected from de novo DNA 
methylation during development. 
DNA methyltransferase enzymes DNMT3A and DNMT3B, complexed with 
DNMT3L are responsible for de novo DNA methylation (Jia et al. 2007; Ooi et 
al. 2007). DNMT3A and DNMT3B show methyltransferase activity only on 
unmethylated DNA (CpG sites) (Okano et al. 1999). Some distinction between 
the functions of DNMT3A and DNMT3B has been achieved. DNMT3B -/- ES 
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cells lack methylation in minor satellite repeats located in centromeres, 
however DNMT3A -/- ES cells do not (Okano et al. 1999). DNMT3L is a 
closely related homologue that co-localises with DNMT3A and DNMT3B. 
DNMT3L lacks methyltransferase activity itself, but it recruits the 
methyltransferases to DNA by binding to H3 in the nucleosome. Consistent 
with the finding of anti-correlation between DNA methylation and the presence 
of methylated H3K4, contact between DNMT3L and the nucleosome is shown 
to be inhibited by all forms of methylation on H3K4 (Ooi et al. 2007). 
Following differentiation, cells generally lose both their de novo DNA 
methylation activity and their ability to recognise and protect CpG islands. 
However, the basic DNA methylation pattern that is generated at the time of 
implantation is maintained throughout development due to actions of DNMT1 
(Chuang et al. 1997). DNMT1 is associated with the replication complex and 
acts preferentially on hemimethylated DNA during replication to maintain 
methylation pattern through cell division (Gruenbaum et al. 1982; Leonhardt et 
al. 1992). It seems that the DNA methylation profile can act as a template to 
reconstructing epigenetic sate of the genome following each cell division. 
Methylated regions of DNA are reassembled in a closed configuration 
(heterochromatin) whereas unmethylated regions tend to get packaged into 
more open configurations (euchromatin) (Howard 2009). Consistent with this 
statement it was reported that the heterochromatin binding protein 1 (HP1) has 
the ability to recruit DNMT1 protein to mediate silencing of euchromatic genes 
(Smallwood et al. 2007). 
DNMT2 has a weak DNA methyltransferase activity (Hermann et al. 2003) 
and is not essential for either global de novo or maintenance of the DNA 
 21 
methylation in embryonic stem (ES) cells (Okano et al. 1998), but it is required 
for methylation of aspartic acid transfer RNA (tRNA(Asp)) (Goll et al. 2006). 
1.1.4 Relationship between DNA methylation and histone 
modification 
Although DNA methylation and histone modifications are carried out by 
different chemical reactions and different enzymes, there seems to be a close 
biological relationship between the two. It seems that the relationship can work 
in both directions: DNA methylation can serve as a template for some histone 
modifications after DNA replication, and histone methylation can direct DNA 
methylation (reviwed in Cedar et al. 2009). An example of how histone 
modification can effect DNA methylation was mentioned above. All forms of 
H3K4 methylation inhibit recruitment of DNA methyltransferases to that site 
by DNMT3L (Ooi et al. 2007). On the other hand, requirement of the DNA 
methyltransferase enzymes DNMT3A and DNMT3B for activity of the histone 
methyltransferase enzymes SUV39H1 and SUV39H2 (Lehnertz 2003, Fuks 
2003), demonstrates how DNA methylation is involved in histone 
modification. 
There is also evidence that DNA methylation is important for maintenance of 
patterns of histone modifications through cell division. It is likely that the 
replication fork disrupts the chromatin structure as it progresses along the 
DNA. Although not clearly understood, it seems that the DNA methylation 
pattern established during early development acts as a template to maintain the 
histone modification pattern throughout the cell division. Methylation of DNA 
at specific sites can modulate histone covalent modification through the 
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recruitment of methyl-binding proteins such as methyl-CpG- binding protein 2 
(MeCP2). MeCP2 is an abundant nuclear protein encoded on the X 
chromosome; it is part of a complex that also consists of histone deacetylase 
(HDAC) and the co-repressor Sin3a that controls transcription through the 
deacetylation of core histones at the methylated regions (Jones et al. 1998; Nan 
et al. 1998). MeCP2 has an N-terminal, methyl-CpG binding domain (MBD) 
and a transcriptional repressor domain (TRD) (Nan et al. 1993). Presence of 
DNA methylation at a specific site also inhibits H3K9 dimethylation, perhaps 
through interactions of DNMT1 and G9a, a histone methyltransferase, with the 
replication complex (Esteve et al. 2006). There is also evidence that the DNA 
methylation inhibits H3K4 methylation (Lande-Diner et al. 2007), which is a 
marker associated with transcription activation. 
There are still many mechanical details of how DNA methylation and histone 
modifications are coordinated at the molecular level that needs to be clarified. 
For example it is not clear how DNA methylation pattern is actually translated 
to produce the correct histone modification profile. There are also mysteries 
about how the formation of histone methylation patterns may affect de novo 
DNA methylation, because the presence of methylated H3K9 or H3K27 does 
not always lead to recruitment of DNMT3 proteins and de novo DNA 
methylation (Cedar et al. 2009). 
1.2 Chromatin structure and disease 
In 1995, Strohman VXJJHVWHG WKDW ZH ³UHGLUHFW RXU DWWHQWLRQ WR HSLJHQHWLF
UHJXODWLRQ DV D VHFRQG LQIRUPDWLRQDO V\VWHP LQ SDUDOOHO ZLWK WKH JHQRPH´ WR
understand complex disease traits (Strohman 1995). Genomic DNA must exist 
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in a particular chromatin configuration and hence the genotype can only give 
rise to a phenotype through the epigenotype. The epigenotype shows far 
greater plasticity than the genotype in the normal development of an 
individual, and therefore it is reasonable to speculate that epigenetic errors 
could be a major contributor to human diseases (Jiang et al. 2004). It is now 
widely appreciated that modification of chromatin structure is integral to the 
correct control of gene expression in mammals. Several human genetic 
disorders result from mutation in components of chromatin or in enzymes 
involved in regulation of chromatin structure, these include Immunodeficiency 
Centromeres instability and Facial anomalies (ICF) syndrome, Rett syndrome 
(RTT) and Alpha-Thalassemia mental Retardation, X-linked (ATR-X) 
syndrome. 
ICF syndrome is a rare recessive disease caused by mutation in the gene 
encoding the de novo DNA methyltransferase, DNMT3B (Hansen et al. 1999; 
Xu et al. 1999). DNMT3b mutations in ICF patients most likely impair, rather 
than completely abolish, the methyltransferase enzyme activity. There is no 
genome-wide hypomethylation in the DNA of ICF patients, but the 
hypomethylation is targeted to specific sequences such as satellite DNAs 2 
(Jeanpierre et al. 1993) and the non-satellite repeats D4Z4 and NBL2 (Kondo 
et al. 2000). 
 RTT syndrome is a form of mental retardation that is caused by mutation in 
the gene at Xq28 that encodes the methylated-DNA binding protein MECP2 
(Amir et al. 1999). MeCP2 is part of a transcription repressor complex and is 
thought to be responsible for silencing of certain neural genes (Stancheva et al. 
2003). Moreover, it has been proposed that the extensive DNA replication-
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independent replacement of H3 in neurons may rely on MeCP2 (Ahmed and 
Henikoff 2002). As discussed in section 1.1.4, there is a close interplay 
between DNA methylation and chromatin modifications. Therefore it is likely 
that silencing of certain genes involved in neurological development relies on 
DNA methylation and recruitment of MeCP2 (Stancheva et al. 2003).  
 ATR-X syndrome is associated with mutation in ATRX, an ATP-dependant 
chromatin remodeling protein. Abnormal levels of DNA methylation at 
repetitive elements have been reported in ATR-X patients (Gibbons et al. 
2000). ATRX and MeCP2 were found to interact in vitro and co-localise at 
pericentromeric heterochromatin (Nan et al. 2007). Recently, it was reported 
that ATRX is required for normal recruitment of MeCP2, cohesin and the 
insulator protein CTCF. Hence loss of the protein in ATRX probably alters the 
expression of a connected network of imprinted genes in the postnatal brain 
(Kernohan et al. 2010). MeCP2 and cohesin are known to be involved in 
chromosomal looping (Horike et al. 2005; Hadjur et al. 2009), which suggests 
that ATRX may also be involved in chromatin loop formation and long-range 
chromatin interactions (Cunningham et al. 2010). Involvement of cohesin in 
the complex sheds light on the importance of cohesin for correct gene 
regulation. 
Facioscapulohumeral Dystrophy (FSHD) is another disease that may be caused 
by alterations in chromatin structure. Although FSHD was linked to deletions 
within the macrosatellite, D4Z4, in 1992 (Wijmenga et al. 1992) the 
underlying mechanism of whereby these deletions cause FSHD is still unclear. 
Several disease mechanisms have been proposed to explain how FSHD is 
caused, most of which predict a chromatin structure change followed by loss of 
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control over expression of genes in or proximal to the D4Z4 repeats (reviewed 
by de Greef et al. 2008) . This study will further investigate the association of 
previously identified chromatin structure changes involved in FSHD 
pathogenesis. 
1.3 FSHD 
Facioscapulohumeral muscular dystrophy (FSHD) is the third most common 
form of muscular dystrophy with an incidence of 1 in 20,000 in the Caucasian 
population (Wijmenga et al. 1990; Lunt et al. 1991). FSHD is an autosomal 
dominant disorder that in most cases presents in the second decade of life and 
is predominantly charactarised by progressive weakness and atrophy of a 
highly selective muscle group (van der Maarel et al. 2005; Tawil et al. 2006). 
The onset of FSHD involves the weakening of certain facial muscles, such that 
patients may not be able to smile or close their eyes. As the disease progresses 
the muscular weakness spreads to the shoulders and upper arm muscles. In 
more severe cases the weakness can also affect the abdominal and foot 
extensor muscles affecting WKHSRVWXUHDQG WKH LQGLYLGXDO¶VDELOLW\ WRZDON. A 
notable characteristic feature of the disease is that the muscle weakness 
displays an asymmetric distribution (Lunt et al. 1991). Additional non-
muscular symptoms such as deafness, retinovasculopathy, mental retardation 
and epilepsy are associated mostly with more severely affected patients 
(Funakoshi et al. 1998). There is a wide variability in the disease penetrance 
amongst the FSHD patients, ranging from individuals with very mild muscle 
weakness, who are almost unaware of being effected, to patients who are 
wheelchair dependant. 
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Almost all FSHD cases (~95%) show linkage to a polymorphic EcoRI 
fragment on the subtelomeric region of chromosome 4q35 (Wijmenga et al. 
1991). Cloning of this EcoRI fragment revealed a highly polymorphic array of 
3.3kb KpnI repeats (Figure 1.2) (Vandeutekom et al. 1993; Hewitt et al. 1994) 
that has been named D4Z4. In unaffected individuals the number of the 3.3kb 
repeats varies between 11 and 100, equivalent to EcoRI fragment of 40-300kb. 
However in the majority of FSHD patients the D4Z4 repeat array is contracted 
to 10-40kb containing 1 to 10 repeat units (Figure 1.3) (Wijmenga et al. 1992). 
Alleles with 1-3 repeats are usually correlated with the earlier age of onset and 
more severe phenotypes, although a linear relationship between the two has not 
been observed (Lunt et al. 1995; Tawil et al. 1996). However, loss of a 
complete D4Z4 array on one allele does not result in FSHD, suggesting that the 
repeats themselves play a direct role in this disease (Tupler et al. 1996).  
Mosaicism for the D4Z4 contraction is a frequent observation in FSHD (Tawil 
et al. 2006). Mitotic D4Z4 contractions can be encountered in 40% of de novo 
families, equally divided between affected mosaic patients and non-affected 
mosaic carriers parents of a non-mosaic affected child (Tawil et al. 2006). The 
male karyotype has a prominent effect in mosaic cases, where mosaic males 
are most affected despite having an equal complement of affected cells to a 
mosaic female. Mosaicism can directly affect the disease presentation and 
transmission risk, if present in the germ line (Tawil et al. 2006). 
What makes the picture even more complex is the fact that around 5% of 
FSHD patients show no contraction of D4Z4 on chromosome 4q (termed 
phenotypic FSHD or FSHD2) (Gilbert et al. 1993). These patients share 
epigenetic changes at the D4Z4 locus with patients with the contraction, 
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suggesting that this disease mechanism is also mediated through D4Z4 (van 
Overveld et al. 2003; de Greef et al. 2007). Although FSHD was linked to the 
4q35 D4Z4 repeats in 1992 (Wijmenga et al. 1992) the underlying mechanism 
of whereby these deletions cause FSHD is still unclear. 
 
 
 
Figure 1.2 The EcoRI fragment identified by the p13E-11 probe. 
P13-E11 (D4F10451) region is used as a DNA probe to identify the EcoRI 
fragment. Each arrowhead represents one 3.3Kb KpnI repeat and the sequence 
motifs within each individual repeat are shown. Each repeat consists of two 
low copy CG-rich repeat elements, LSau and Hhspm3 and an open reading 
frame (ORF) encoding a putative transcription factor with two homeodomains 
known as DUX4. 
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Figure 1.3 Southern analyses with p13E-11 of EcoRI-digested DNA from 
new cases of FSHD.  
In four of the five different cases of FSHD a new EcoRI fragment (arrowhead) 
is present which is absent in either unaffected parent. The length of the EcoRI 
fragment is different in all affected individuals and varies between 14-28 kb. 
Image taken from Wijmenga et al. (1992). 
 
1.3.1 D4Z4 array 
D4Z4-like repeats are not restricted to chromosome 4qter. Sequences 
homologous to D4Z4 have been identified on the short arm of the acrocentric 
chromosomes (Wijmenga et al. 1992; Hewitt et al. 1994; Winokur et al. 1994). 
As a result of an ancient duplication a similar tandem array is located on 
chromosome 10q26 that has 98% nucleotide identity with the D4Z4 repeats on 
4q35 (Deidda et al. 1995; van Geel et al. 2002). This region of homology starts 
from a region 40kb proximal to the D4Z4 repeats and extends into the 
telomeric repeat itself (van Geel et al. 2002). Similar to the 4q35 locus, 10q26 
locus is also polymorphic for the number of D4Z4 repeats but short arrays at 
this locus are not associated with FSHD (Lemmers et al. 2001; Zhang et al. 
2001).  Initially the presence of this 10q array complicated the genetic 
diagnosis of FSHD, since the short 10q EcoRI fragments could not be 
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distinguished from those arising from 4q35. In 1996 a BlnI recognition site was 
found to be specific to 10q array (Deidda et al. 1996). Hence a double 
digestion with EcoRI and BlnI is now used for the genetic diagnosis of FSHD 
(Deidda et al. 1996).  
There are two variants of the 4q subtelomere, termed 4qA and 4qB (van Geel 
et al. 2002). The most prominent difference between these two variants is the 
presence of a region of ß-satellite DNA distal to D4Z4 on 4qA type alleles, 
which is absent from the 4qB chromosomes (Figure 1.4E) (van Geel et al. 
2002). Despite the equal frequencies of A and B alleles in the population, 
FSHD is exclusively associated with contracted D4Z4 repeats on the 4qA allele 
variant (Lemmers et al. 2002; Lemmers et al. 2004).  
There are multiple haplotypes of chromosome 4q identified based on simple 
sequence length polymorphisms (SSLP) situated 3.5kb proximal to the repeats 
(Figure 1.4B) and a G/C single nucleotide polymorphism (SNP) on the first 
repeat (Figure 1.4D). In addition, there are fifteen different SNPs in the p13-
E11 (D4F104S1) region (Figure 1.4C) (Lemmers et al. 2007). So far, 
contraction of D4Z4 repeats only on a certain haplotype of 4qA (4qA161) is 
associated with FSHD. Contraction of D4Z4 on other common haplotypes is 
nonpathogenic (Lemmers et al. 2007), suggesting that the contraction of D4Z4 
repeats is necessary but not sufficient to cause FSHD (Lemmers et al. 2004). It 
is thought that certain SNPs might alter the chromatin structure of the 4q 
region resulting in the disease phenotype (Lemmers et al. 2007). 
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Figure 1.4 Schematic overview of the 4q and 10q subtelomeric region and 
the key sequence variations.  
(A) Chromosomal localisation of the D4Z4 repeats, chromosome 4q or 10q. 
(B) This simple sequence length polymorphism (SSLP) is a combination of 
five variable number tandem repeats (VNTRs): a 8bp insertion/deletion, two 
SNPs localised 3.5kb proximal to D4Z4 and varies in length between 157-
182bp. (C) the p13-E11 (D4F104S1) is localised immediately proximal to 
D4Z4, is 475bp in length and contains 15 SNPs. (D) The most proximal D4Z4 
unit contains several SNPs. (E) The two variants of the subtelomeric region 
distal to D4Z4. Image modified from Lemmers et al. 2010. 
 
1.3.2 Repressor complex associated with D4Z4  
To investigate whether the D4Z4 region has any involvement in transcriptional 
control of the 4q35 genes, the interaction between D4Z4 and nuclear proteins 
was analysed using an electrophoretic mobility shift assay (EMSA) (Gabellini 
et al. 2002). This study revealed that a 27bp sequence, called the D4Z4 binding 
element (DBE) within the D4Z4 region, supported formation of a repressor 
protein complex (Gabellini et al. 2002). This repressor protein complex 
comprises of YY1 (Ying Yang 1), HMGB2 and nucleolin, termed the D4Z4 
repressing complex (DRC) (Gabellini et al. 2002). YY1 is a complex protein 
involved in repression and activation of a number of genes. YY1 is known to 
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interact with numerous key regulatory proteins, suggesting that these 
interactions are important for determining whether YY1 is involved in gene 
repression or activation (Thomas et al. 1999). Since DBE contains a putative 
YY1 recognition sequence, CCATN (Yant et al. 1995), YY1 is the most likely 
component of DRC to interact directly with the DBE within D4Z4 (Gabellini et 
al. 2002). HMGB2 is a member of one of the three families of high mobility 
group (HMG) proteins. A yeast two-hybrid screen identified SP100 to interact 
with HMGB2. SP100 in turn interacts with HP1, the heterochromatin binding 
protein. This raises the possibility that HMGB2 might be involved in 
heterochromatin formation/maintenance (Lehming et al. 1998).  
It has been proposed that contraction of the D4Z4 repeats may result in 
decreased repressor complex binding, leading to miss-regulation of distant 
neighboring genes (Gabellini et al. 2002). Loss of control is proposed to occur 
through cis-looping or cis-spreading mechanism, but chromatin studies had 
failed to identify any cis-acting mechanism operating at 4qter in FSHD (Jiang 
et al. 2003) until more recently (Petrov et al. 2006; Pirozhkova et al. 2008; 
Bodega et al. 2009). The findings of these studies are discussed in the next 
section. 
1.3.3 Candidate genes for FSHD and transcription from 
chromosome 4q35 
Assuming that contraction of D4Z4 would influence the transcriptional control 
of genes in cis, the search for a candidate gene for FSHD was focused on the 
region surrounding the D4Z4 repeats (Figure 1.5). D4Z4 lies adjacent to a 
subtelomeric sequence, which is within 20-30kb of a telomeric repeat (van 
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Geel et al. 2002) and no genes have been described or predicted distal to the 
array. The first gene identified in the 4qter was FSHD region gene 1 (FRG1) 
situated at 120kb proximal to D4Z4 (vanDeutekom et al. 1996), encoding a 
nuclear protein involved in RNA biogenesis (van Koningsbruggen et al. 2007). 
Chromatin conformation capture (3C) experiments have been taken to indicate 
that D4Z4 physically interacts with the promoter region of the FRG1, which 
represses FRG1 expression in myoblasts (Bodega et al. 2009). Using 
chromatin immunoprecipitation (ChIP) data coupled with data obtained from 
3D fluorescence in situ hybridisation (3D-FISH), it was revealed that during 
normal myogenic differentiation this interaction is loosened and FRG1 
expression is up-regulated (Bodega et al. 2009). A small reduction in the 
frequency of loop formation between D4Z4 array and FRG1 promoter region 
was observed in FSHD myoblast with contracted D4Z4, but the difference was 
too small to be involved in mis-regulation of FRG1 gene expression (Bodega et 
al. 2009). Previously, Gabellini et al. had reported altered expression of FRG1 
(2002) and later on showed that over-expression of Frg1 in mice induced a 
muscle phenotype (Gabellini et al. 2006). However, FRG1 expression in FSHD 
muscle is highly controversial as several other groups have failed to observe 
FRG1 up-regulation (vanDeutekom et al. 1996; Gabellini et al. 2002; Jiang et 
al. 2003; Winokur et al. 2003; Masny et al. 2010). Expression studies have 
yielded different results, possibly as a consequence of different sources of 
RNA (site of muscle biopsy, severity of pathology) and different methods to 
detect expression (Tawil et al. 2006). It has also been suggested that since 
FRG1 is a multiple copy gene, also present on chromosomes 8, 9, 12, 20 and 
 33 
all of the acrocentric chromosomes, some of the positive expression signals 
may come from these sites (Masny et al. 2010). 
The closest putative gene to D4Z4 is situated 37kb proximal to the repeats and 
is termed FSHD region gene 2 (FRG2) (Rijkers et al. 2004). FRG2 was found 
to be expressed in differentiated FSHD primary myoblast cultures, but not in 
those of control individuals (Rijkers et al. 2004). The FRG2 homologue on 
chromosome 10q was also found to be upregulated in differentiating FSHD 
myoblasts. However, FRG2 absence from 4q in some FSHD patients carrying a 
proximally extended deletion of D4Z4 (Lemmers et al. 1998; Lemmers et al. 
2003) makes the involvement of this gene in FSHD pathogenesis less likely.  
Approximately 40kb proximal to D4Z4, lies an inverted and truncated copy of 
a D4Z4 unit (Wright et al. 1993). This inverted unit defines the proximal 
boundary of the region of homology between chromosome 4q35 and 10q26 
and also contains a putative double homeobox gene DUX4C (double 
homeobox 4 centromeric), which is absent on chromosome 10q (van Geel et al. 
2002). Expression of DUX4C had not been documented until recently. In 2008 
a study indicated a possible function for DUX4C in differentiation of mouse 
C2C12 cells (a mouse myoblast cell line) (Bosnakovski et al. 2008). More 
recently Ansseau et al. (2009), reported the presence of a putative promoter, 
which was shown to be functional by fusion upstream of a luciferase reporter 
gene and transfection of C2C12, TE671 and HeLa cells (2009). In the same 
study, it was shown that the over-expression of DUX4C could activate human 
myoblast proliferation and inhibit their differentiation in vitro. It was suggested 
that this process might be caused by DUX4C inducing MYF5 myogenic 
regulator and its DNA-binding activity (Ansseau et al. 2009). However, there 
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are a number of FSHD patients with a proximal deletion that extends to the 
inverted repeat and hence DUX4C cannot be causative of FSHD.  
Another extensively studied FSHD candidate gene is TUBB4Q (Tubulin, beta 
polypeptide 4, member Q). Although only 80kb proximal to D4Z4, and hence, 
positionally a good candidate, TUBB4Q is most likely to be a pseudogene (van 
Geel et al. 2000).  
Some genes at a larger distance from D4Z4 have also been considered for their 
involvement in FSHD. At around 3.5Mb proximal lies the adenine nucleotide 
translocator-1 gene (ANT1) (Li et al. 1989). ANT1 is involved in the export of 
ATP through the mitochondrial membrane and is highly expressed in heart and 
skeletal muscles (Stepien et al. 1992). ANT1 is also known to be involved in 
apoptosis (Doerner et al. 1997). There is evidence for up-regulation of ANT1 
at the protein level in affected and unaffected FSHD muscles (Laoudj-
Chenivesse et al. 2005); however, further verification from independent studies 
is required.  
 
 
Figure 1.5 Illustration of the positioning of the D4Z4 region on 4q and the 
known genes proximal to the repeats.  
The genes are shown using pink boxes and their distance from the D4Z4 
repeats is shown under each gene. The diagram is not drawn to scale. 
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In summary there is little plausible evidence for the involvement of genes 
proximal to D4Z4 in FSHD. 
The D4Z4 unit itself, as outlined in Figure 1.2, consists of several sequences 
known to be associated with heterochromatin regions, such as low copy CG-
rich repeat elements LSau and hhspm3 (Zhang et al. 1987; Hewitt et al. 1994; 
Winokur et al. 1994, Meneveri, 1993 #82; Lee et al. 1995). In addition, each of 
the 3.3kb repeats contains an 1173bp open reading frame (ORF) encoding a 
putative transcription factor with two homeodomains (Hewitt et al. 1994). This 
ORF is now known as DUX4 (double homeobox 4) (Gabriels et al. 1999) and 
is thought to behave as a transcriptional activator (Kawamura-Saito et al. 
2006). The DUX4 ORF has been evolutionary conserved for over 100 million 
years, which supports the idea of an protein coding function for DUX4 (Clapp 
et al. 2007). These findings, in addition to the positioning of the DUX4 ORF, 
make this gene a strong candidate for FSHD. 
Cells transfected with DUX4 constructs showed characteristic markers of 
apoptosis suggesting that the protein was toxic to the cells (Gabriels et al. 
1999; Kowaljow et al. 2007). However, the toxicity of DUX4 could be derived 
from its over-expression and therefore may not indicate the real function of 
DUX4 in vivo. Exogenous expression of DUX4 was shown to activate transient 
expression of a luciferase reporter gene fused to the Pitx1 (paired-like 
homeodomain transcription factor 1) promoter as well as the endogenous Pitx 
gene in transfected C2C12 cells (Dixit et al. 2007). Additionally, genome-wide 
expression data from muscle biopsies of FSHD patients showed up-regulation 
of PITX1 transcription in comparison with 11 other neuromuscular disorders 
(Dixit et al. 2007). However, the data from this study is not supported by other 
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studies of global gene expression analysis by different groups (Tupler et al. 
1999; Winokur et al. 2003; Celegato et al. 2006). 
A putative promoter region 149bp upstream of the ORF was inserted upstream 
of a luciferase reporter gene and was used to transfect TE671 cells. Expression 
of the reporter gene verified that the region could act as a functional promoter 
(Gabriels et al. 1999). Nevertheless, confirmation of the expression of full-
length RNA and protein from the DUX4 ORF has been somewhat challenging. 
However, a recent study has reported a low abundance of DUX4 protein and 
transcripts in some FSHD cells (Dixit et al. 2007). A later study reported the 
transcription of several overlapping sense and anti-sense RNA transcripts from 
the 4q D4Z4 region (Snider et al. 2009). Although a full-length DUX4 
transcript that can be detected at low levels is initially produced in muscle 
cells, spliced and cleaved forms are at higher abundance. Cleavage and 
processing of the DUX4 transcript generates mi/siRNA (small interference 
RNA)-sized fragments that might have a function in local or distance 
chromatin silencing or even target RNA from other loci (Snider et al. 2009). 
In summary, the most convincing evidence suggests that DUX4 is the best 
candidate gene for FSHD. As mentioned above, maintenance of at least one 
D4Z4 repeat is essential for the FSHD pathogenesis (Tupler et al. 1996), which 
indicates the important role the D4Z4 repeats themselves play in FSHD 
pathogenesis. 
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1.3.4 Sub-nuclear localisation of 4q35 
Chromosomes occupy distinct territories in the mammalian nucleus. These 
chromosome territories often reflect the gene density, transcriptional activity, 
size and replication timing (Sun et al. 2000; Tanabe et al. 2002). Unlike all 
other chromosomal ends studied, including 10qter, 4qter preferentially 
localises at the nuclear periphery, independent of cell type and chromosome 
territory effects (Masny et al. 2004; Tam et al. 2004). It is not the D4Z4 
repeats themselves, but sequences proximal to the D4Z4 that are necessary for 
the perinuclear localisation (Masny et al. 2004). This might explain the 
difference between 4qter and the 10qter nuclear localisation, since the 98% 
identity between them only extends 40kb proximal to D4Z4. Although no 
difference has been observed in localisation of chromosomes between 
unaffected individuals and FSHD patients, the perinuclear localisation of the 
4qter is largely lost in fibroblast lacking lamin A/C (Masny et al. 2004). 
Mutation in lamin A/C is known to cause Emery-Dreifuss muscular 
dystrophies (EDMD), thus raising the possibility that FSHD is related to these 
nuclear envelope muscular dystrophies (Bakay et al. 2006). More recently it 
was shown that the D4Z4 macrosatellite repeat acts as a CTCF and A-type 
lamins-dependant transcription insulator and it behaves as a strong perinuclear 
cis-acting positioning element in FSHD, properties that are lost upon 
multimerisation of the repeats (Ottaviani et al. 2009). The same group later 
showed that CTCF and A-type lamin only contribute to and are not essential to 
the positioning of D4Z4, indicating additional pathways for the anchoring of 
this region (Ottaviani et al. 2009). The proposed model for the effects of D4Z4 
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contraction/demethylation in FSHD on 4q35 perinuclear positioning is shown 
in Figure 1.6. 
 
 
 
 
Figure 1.6 A model for tethering of the 4q35 locus at the nuclear 
periphery.  
(A) In normal cells, D4Z4 repeats are methylated and therefore are not bound 
by CTCF. The 4q35 region is attached to the nuclear periphery through a 
lamin-A-dependant tethering site located outside the D4Z4 array. (B) In FSHD 
cells contraction of the D4Z4 repeats allows the binding of CTCF and the 
D4Z4 repeats become specifically attached to the periphery. This higher order 
switch is thought to modify the expression of FSHD-associated genes probably 
by preventing their repression (Ottaviani et al. 2009). 
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1.3.5 DNA methylation at D4Z4 
Human D4Z4 repeats are extremely CG-rich, making them attractive 
candidates for DNA methylation. Hypomethylation of the proximal D4Z4 
repeats in patients with 4q-linked and phenotypic FSHD was observed in both 
mutated and wild type allele with no tissue-specific methylation differences 
between DNA isolated from blood lymphocytes and muscles (van Overveld et 
al. 2003). In 2009 de Greef et al. showed that the D4Z4 contraction below a 
certain threshold results in significant hypomethylation, regardless of the 
haplotype on which D4Z4 contraction occurs (2009). In addition, D4Z4 
methylation was observed not only on both chromosome 4q, but also on both 
chromosomes 10q in phenotypic FSHD patients. This argues that an underlying 
genetic defect, which is responsible for methylation of D4Z4 repeats, exists in 
FSHD2 patients (de Greef et al. 2009). 
More severe hypomethylation at the 4q and 10q repeats is observed in a 
different group of patients with immunodeficiency-centromeric insatiability-
facial anomalies (ICF) (Kondo et al. 2000; van Overveld et al. 2003). ICF 
syndrome presents with immunodeficiency, facial anomalies, mental 
retardation and developmental delay and is caused by mutations in DNMT3B 
(Xu et al. 1999). As these mutations reduce the methyltransferase activity of 
DNMT3B, hypomethylation of number of repeat arrays, including satellite 2 
(Sat2), satellite 3 (Sat3), the NBL2 repeat and the D4Z4 repeat, is observed in 
ICF patients (Jeanpierre et al. 1993; Xu et al. 1999; Kondo et al. 2000). Since 
the clinical presence of ICF syndrome shares no similarity with FSHD and 
seeing as D4Z4 hypomethylation occurs on non-permissive haplotypes in 
unaffected individuals (de Greef et al. 2009), it can be said that the 
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hypomethylation of the D4Z4 allele alone is not sufficient to cause FSHD. 
Other epigenetic factors or haplotype-specific sequence polymorphisms may 
eventually determine the underlying mechanism to development of the FSHD 
phenotype (de Greef et al. 2009). 
1.3.6 Histone modifications at D4Z4 repeat 
As discussed previously, DNA methylation is often associated with increased 
chromatin condensation and gene inactivation. The D4Z4 repeat array is often 
considered heterochromatic, mainly because of the presence of the low copy 
repeats hhspm3 and LSau, which are mainly found in heterochromatic regions 
of the human genome (Hewitt et al. 1994). However, several studies have 
reported that D4Z4 repeat array consists of both heterochromatic and 
euchromatic regions (Jiang et al. 2003; Yang et al. 2004; Zeng et al. 2009). 
Double-ChIP analysis has revealed that H3K9me3 coincide with H3K27me3, 
but not H3K4me2, suggesting that the D4Z4 repeats contain distinct 
heterochromatin regions, marked by H3K9me3 and H3k27me3 as well as 
euchromatin regions, marked by H3K4me2 (Zeng et al. 2009). 
In a recent study, Zeng et al. employed ChIP analysis to examine the D4Z4 
chromatin structure at the DUX4 promoter and a region within the DUX4 ORF 
(2009). ChIP analysis on the non-FSHD lymphoblasts revealed the presence of 
H3K9me3, H3K27me3, H3K4me2 and H3Ac histone modifications, but the 
absence of H3K4me3 at these regions. The same study revealed the presence of 
H3K4me2 and H3K9me3 at the D4Z4 site in human embryonic stem (hES) 
cell, suggesting that D4Z4 chromatin domains are marked by these histone 
modifications early on in development and are maintained throughout 
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differentiation. This was in contrast to H3Ac which was absent in hES and 
added on at a later stage (Zeng et al. 2009). Additionally, an independent study 
reported that the levels of H3K27me3 at D4Z4 are significantly reduced after 
myogenic differentiation (Bodega et al. 2009). 
Zeng et al. (2009) reported a significant decrease in H3K9me3 signals at D4Z4 
in both FSHD1 (D4Z4 contraction) and FSHD2 (no contUDFWLRQ SDWLHQW¶V
myoblasts, fibroblast and lymphoblasts when compared to normal cells from 
healthy individuals (figure 1.7, Zeng et al. 2009). Using a 4q/10q sequence 
variant at the D4Z4 region under study, it was verified that D4Z4 on both 4q 
and 10q undergo the same H3K9me3 modification (Zeng et al. 2009). None of 
the other forms of muscular dystrophies tested in this study, namely Duchenne 
muscular dystrophy (DMD) and limb-girdle muscular dystrophy (LGMD), 
showed any significant loss of H3K9me3 at D4Z4. Hence, it was concluded 
that the loss of H3K9me3 at 4q and 10q at D4Z4 repeats appear to be a change 
uniquely associated with FSHD patients (Zeng et al. 2009). 
DNA methylation is shown to be the downstream consequence of H3K9 
methylation (Lachner et al. 2002), but in some instances DNA methylation was 
shown to promote trimethylation of H3K9 (Sarraf et al. 2004). Hence the loss 
of H3K9me3 may have been the downstream effect of the hypomethylation of 
the D4Z4 repeats in FSHD patients. However, H3K9me3 was largely intact in 
ICF patient cell lines, which, as previously reported, carry severe 
hypomethylation at the D4Z4 repeats on 4q and 10q sites (van Overveld et al. 
2003; de Greef et al. 2009; Zeng et al. 2009). This suggested that the loss of 
H3K9me3 at the D4Z4 repeats is a change distinct from the DNA 
hypomethylation (Zeng et al. 2009). These findings imply that the loss of 
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H3K9me3 at D4Z4 repeats, rather than DNA hypomethylation, is casually 
involved in FSHD (Zeng et al. 2009). 
 
 
Figure 1.7 H3K9me3 is lost in both 4q-linked and phenotypic FSHD.  
(A) ChIP analysis of H3K9me3 and H3K27me3 at D4Z4 in normal and FSHD 
(4qF) myoblasts. 4qHOX region lies within the DUX4 ORF and rDNA region 
serves as a positive control. (B) H3K9me3 is specifically lost in fibroblasts. 
Endpoint PCR analysis with 4qHOX primers is shown on an agarose gel and 
quantitation of real-time PCR with Q-PCR primers, which lie upstream of 
DUX4 ORF, are shown as a bar chart. D4Z4 repeat numbers for 4q and 10q 
and the total repeat number for each cell line is indicated in the Table. (H) 
Non-FSHD cell line (Pfaffl et al. 2004) phenotypic FSHD cell line (4qF) 4q-
linked FSHD cell line. Image adopted from Zeng et al. (2009). 
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1.4 Chromatin Immunoprecipitation (ChIP) assay 
was first developed in 1988 for cultured Drosophila cells (Solomon et al. 
1988). ChIP is now the most widely used technique for mapping the in vivo 
distribution of proteins associated with chromosomal DNA such as histones, 
transcription factors, regulatory proteins etc (Alexiadis et al. 2007; Bodega et 
al. 2009; Zeng et al. 2009). ChIP can be used to identify regions that are 
associated with these proteins, or conversely, it can be used to identify proteins 
that are associated with a particular region of the genome.  
ChIP methodology often involves protein-DNA and protein-protein 
crosslinking, which consists of treating cells or tissues with formaldehyde. The 
chromatin is extracted and is fragmented prior to immunoprecipitation with an 
antibody specific to a target protein associated with the chromosomal DNA. 
Reversal of the protein-DNA crosslink prepares the DNA fragments for 
identification. The ChIP procedure is summarised in Figure 1.8. There is 
variety of identification procedures that can be employed including PCR, DNA 
microarray and DNA sequencing. Standard or quantitative PCR can be 
preformed to verify whether a particular region of the genome is associated 
with the protein of interest (Garrick et al. 2008; Zeng et al. 2009). The 
combination of ChIP and microarray (ChIP-CHIP) allows genome-wide 
identification of binding sites for the chromatin-associated proteins (De Gobbi 
et al. 2007; Pauler et al. 2009). Alternatively, high throughput sequencing of 
the immunoprecipitated DNA (ChIP-Seq) offers a more precise way of 
mapping protein-DNA interactions across the genome (Pauler et al. 2009).  
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The main drawback of ChIP its inherent variability (Mukhopadhyay et al. 
2008). ChIP is a multi-step procedure and hence some level of variability is to 
be expected. The variability in the final results may arise from variability in the 
crosslinking step, immunoprecipitation or the protein-DNA washing stage. A 
number of carefully chosen controls are needed to account for the variability in 
these steps. Other limitations of ChIP analysis include the dependence on the 
availability of a highly specific antibody as well as broad expression of the 
DNA-binding protein of interest (Mukhopadhyay et al. 2008). 
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Figure 1.8 a summary of chromatin immunoprecipitation (ChIP) assay 
 
 
 
CrosslinkingȈFormaldehyde treatment crosslinks proteins 
to DNA to ensure co-precipitation
Cell lysis and SonicationȈSonication shears the chromatin to generate 
200-700bp of DNA to achieve a high degree 
of resolution during the detection stepȈThe average fragment size is verified by gel 
electrophoresis
ImmunoselectionȈEnrichment of a specific DNA-protein 
complex of interest. A primary antibody is 
used in combination with protein A or G-
conjugated solid support matrix such as 
agarose or magnetic beads
Reversal of crosslinkingȈThe crosslinking is reversed by proteinase K 
treatmentȈThe elute is purified to remove the 
chromatin proteins and to prepare the DNA 
for the detection step
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As mentioned above, quantitative real-time PCR (qPCR) can be employed as 
the method of detection to analyse the ChIP data. qPCR allows close analysis 
of the histone composition at specific regions of interest within the genome. 
Section 1.5 explains the basis of qPCR methodology: 
1.5 Quantitative real-time PCR (qPCR) 
Quantitative real-time PCR (qPCR) is a method for DNA amplification in 
which fluorescent dyes that interact with the DNA are used to detect the 
amount of PCR product amplified after each PCR cycle (Higuchi et al 1992).  
Threshold cycle (Ct) is the metric used for analysing qPCR results. The Ct 
value represents the number of cycles needed to reach a set threshold 
fluorescent signal level. Lower number of cycles needed to cross the threshold, 
indicates the greater the amount of starting material and vice versa (Figure 
1.9). Threshold level should be chosen in a way so that it captures data during 
the exponential phase and is the same for all the samples analysed in a qPCR 
run. The threshold value can be chosen either manually or using an instrument-
specific algorithm.  
,QWKLVVWXG\WKHT3&5DVVD\VZHUHFDUULHGRXWRQ&RUEHWW¶V5RWRU-Gene 6000 
and the results were analysed using Rotor-Gene 6000 Software 7.1. The 
threshold value was calculated using the instrument-specific algorithm, which 
was carried out by the software after each run. 
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Figure 1.9 An example of a typical qPCR run.  
The threshold level is set above background fluorescence and at the 
exponential level of amplification. The number of cycles required to reach the 
threshold is determined as Ct value. 
 
1.5.1 Methods of detection: 
1.5.1.1 Target-specific detection 
This method involves the use of an oligonucleotide probe that has a 
complementary sequence to the target region. This probe is constructed to 
FRQWDLQD UHSRUWHU IOXRUHVFHQWG\H IOXRURSKRUHDW WKH¶HQGDQGDTXHQFKHU
G\H DW WKH ¶HQG )OXRURSKRUHV DEVRUE OLJKW HQHUJ\ DW RQH ZDYHOHQJWK DQG
almost immediately re-emit light at another, higher wavelength. Quenchers are 
molecules that can accept energy from fluorophores and then dissipate it 
without light emission. As long as the probe is intact the proximity of the 
quencher absorbs the light emitted by the fluorophore by Fluorescence 
Resonance Energy Transfer (FRET). The specific fluorophore and quencher 
must be matched to each other and to the optic of the qPCR instrument. The 
probes can be labeled with two distinguished reporter dyes, which allow 
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amplification of two different target sequences in one reaction tube. TaqMan 
SUREHVDOVRFDOOHGK\GURO\VLVSUREHVRU¶QXFOHDVHROLJRSUREHVDUH WKHPRVW
commonly used target-specific detection method (Figure 1.10). Other target-
specific detection chemistries include hairpin probes, LightUp probes and 
hybridization probes. 
Although this method offers outstanding specificity and reduction in 
background and false positive signals for qPCR assays, it requires synthesis of 
a different probe for each target sequence, which can be costly. In addition 
prior knowledge of the DNA sequence of the target region is essential for 
designing these probes. 
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Figure 1.10 Schematic diagram of a qPCR reaction using TaqMan probe. 
The probe binds to the target sequence downstream of one of the primers (A). 
7KHSUREHLVFOHDYHGE\WKH¶QXFOHDVHDFWLYLW\RIWKH7DTSRO\PHUDVHDVWKH
primer is extended (c). The cleavage of the probe allows continuous 
amplification of the target sequence as well as removing the fluorophore from 
the close proximity of the quencher, which results in increase in reporter 
signals (C). After each cycle, additional fluorophores are cleaved from their 
respective probes, resulting in increased fluorescent intensity proportionate to 
the amount of amplicon produced. 
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1.5.1.2 Non-specific detection 
This approach uses dsDNA-binding fluorophores for non-specific detection of 
the target DNA sequence. Fluorophore used in non-specific qPCR assays 
exhibit low fluorescence when unbound in solution, but starts to fluoresce 
brightly when associated with dsDNA and exposed to a suitable wavelength of 
light. SYBR green is the most commonly used fluorophore (Figure 1.11). This 
approach was chosen in this study for its simplicity and lower cost. The 
advantage of this method is that it requires less optimization and less 
information about the target sequence. The disadvantage of this approach is 
that only the primers determine the sensitivity and specificity of the qPCR 
assay as the dsDNA-binding fluorophore binds to any dsDNA, even unwanted 
primer dimmer products. For this reason qPCR assays using SYBR green as 
the method of detection, generally include a post-PCR melting curve analysis 
to detect the possible presence of primer dimers or any other unwanted 
products. During the melting curve analysis the qPCR instrument is set to 
gradually increase the temperature and monitor the fluorescence. A sharp drop 
in fluorescence is expected when the temperature is high enough to denature 
dsDNA due to the release of the fluorophore (Figure 1.12). The melting 
WHPSHUDWXUH7PLVFDOFXODWHGE\WKHLQVWUXPHQW¶VVRIWZDUHIURPWKHPHOWLQJ
curve data by plotting negative first derivative (change in fluorescent signals) 
versus temperature (-dF/dT). The Tm of a DNA fragment is dependent on its 
length, G+C content, sequence, strand complementarity, concentration and on 
buffer component. The difference between the melting temperatures allows the 
detection of primer dimers or other nonspecific amplification products, which 
could potentially prevent accurate quantification (Figure 1.12B). 
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Figure 1.11 Schematic diagram of a qPCR reaction using SYBR green.  
SYBR green exhibits low fluorescence when unbound in solution. Upon 
association with dsDNA, SYBR green starts to fluoresce brightly, which 
indicates product synthesis. 
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Figure 1.12 Example of a specific and a non-specific melting curve.  
The derivative melting peak is the highest at the melting temperature. (A) A 
specific melting curve with no primer dimer or unwanted products. (B) A 
melting curve showing three peaks at different melting temperatures indicating 
significant primer-dimer formation or other non-specific amplification during 
this qPCR assay. 
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2. Aims 
The focus of this work will be on further investigation of the association of 
previously identified chromatin structure changes involved in FSHD 
pathogenesis. In 2009 Zeng et al. reported the reduction of H3K9me3 histone 
modification at a specific region within the D4Z4 repeats in FSHD patient cell 
lines. The loss of H3K9me3 at this site was exclusive to FSHD patients and 
independent of DNA hypomethylation at this region. No significant loss of 
H3K9me3 was observed in other repeat sequences analysed (Zeng et al. 2009). 
The first aim of this study will be to repeat and validate the data from Zeng et 
al. (2009). ChIP analysis will be carried out on a number of patient and control 
lymphoblastoid cell lines, using antibodies against four different histone 
modifications, including H3K9me3. The ChIP outcome will be analysed by 
qPCR using SYBR green as the method of detection and D4Z4-specific 
primers used by Zeng et al. (2009). Further to the previous findings, other 
regions within the D4Z4 array will be analysed for any significant change in 
histone composition. 
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3. Materials and Methods 
 
3.1 Growth and maintenance of cells 
3.1.1 Growth and maintenance of patient and control 
lymphoblastoid cell lines 
Lymphoblastoid cell lines grow in suspension with cells clumped in loose 
aggregates. These aggregates can be dissociated by gentle trituration with a 
pipette. All lymphoblastoid lines were grown in 20ml appropriate media (see 
section 3.1.5) in T25 tissue culture flasks at upright position. The cultures were 
seeded at a concentration no lower than 200,000 viable cells/ml. To maintain 
the growth of the cells and avoid the plateau growth level the number of cells 
were kept below 500,000 viable cells/ml. The cells were kept in an incubator at 
Û&ZLWK&22. For the full list of the lymphoblastoid cell lines used in this 
study refer to Table 3.1. 
3.1.2 Growth and maintenance of somatic hybrid cells 
Several human/rodent somatic cell hybrids were used in this study. These cells 
were grown as attached cells in 12ml appropriate media (section 3.1.5) in 
75cm2 tissue culture flasks. For passaging cells, 3 to 5 minutes of incubation 
with 1 x trypsin was performed to detach the cells from the flasks. For the full 
list of the somatic cell hybrids used in this study refer to Table 3.2.
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Table 3.1 Information on the lymphoblastoid cell lines used in this study.   
All the cell lines were obtained from Coriell Cell Repositories. Disease status is indicated for all cell lines. The D4Z4 array size is indicated for 
three the cell lines. The array size is unknown for the other cells. The known haplotypes for each cell line have also been included in this Table. 
GM16351 has not yet been haplotyped. 
ID Disease Status Additional Information Array size Sequence haplotype 
GM08729 Unaffected male Father of an ICF patient  4qB163, 10qA162, CA8CA8CT7+ 
GM16351 FSHD male Clinically affected brother of GM16348   
GM16352 Unaffected female Clinically unaffected sister of GM16348  4qB163, CA9CA8- 
GM16348 FSHD female   4qA161, 4qB168, 10qA166 Hc, 10qA166Hb 
GM17939 FSHD male  4q: 3/33, 10q: 15/26 4qA161, 4qB163, 10qA166c (2 repeat haplotypes) 
GM18207 FSHD male  4q: 3/27, 10q: 18/39 
4qA161 (3 distinct repeat haplotypes), 10qA166, 
CA9CA7+ 
GM18476 Unaffected female  4q: 25/34, 10q: 8.6/12 4qB163, 10qB161Ta 
 56 
ID Background 
Contains human 
chromosome 
Sequence 
haplotype 
4L10 Mouse #4qB  
CY7 Mouse #10q, #16, #12  
GM10115 (HHW416) Chinese hamster  #4 (96% of cells)  
GM10479A Mouse #14 (96% of cells)  
GM11418A Chinese hamster #15 (80% of cells)  
GM11687 Mouse #4 (100% of cells) 4qB163 
GM11688 Mouse #10 (92% of cells) 10qB166 
 
Table 3.2 Information on the somatic cell hybrids used in this study. 
 
3.1.3 Long-term storage of cells 
The cells were pelleted by centrifugation at 600 x g for 3 minutes. The old 
media was removed and the cell pellets were resuspended in 1ml of freezing 
media (appropriate growth media for the cells containing 10% DMSO). The 
cells were then transferred to one or two cryotubes placed in a freezing rack, 
wrapped in bubble wrap and transferred to -Û&IRUDW OHDVWKRXUVEHIRUH
storage in liquid nitrogen. 
3.1.4 Revival of cells from frozen stock 
$SSURSULDWHPHGLDZDVZDUPHG WRÛ&DQG the frozen cells were thawed in 
room temperature. 1ml of appropriate growth media was added to the cells 
before transferring them to a flask of media. The flask was then transferred to 
the incubator and the media replaced the following day. 
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3.1.5 Media used for growth and maintenance of the cell lines 
Cell line Growth Media 
 
Lymphoblastoid lines 
 
 
 
RPMI-1640 
2mM L-glutamine 
15% fetal bovine serum (FBS) 
120U/ml Penicillin 
120µg/ml Streptomycin 
 
Somatic cell hybrids: 
 
HHW416, 4L10, GM14193 DMEM 
2mM L-glutamine 
15% FBS 
120U/ml Penicillin 
120µg/ml Streptomycin 
0.2mM Proline 
 
GM10479A, GM11687, GM11688 +$0¶V)'0(0PL[WXUH 
2mM L-glutamine 
15% FBS 
120U/ml Penicillin 
120µg/ml Streptomycin 
0.25mg/ml Geneticin 
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CY7 +$0¶V) 
2mM L-glutamine 
15% FBS 
120U/ml Penicillin 
120µg/ml Streptomycin 
0.2mM Proline 
 
 
3.2.1 DNA extraction from cultured cell lines 
The salting out procedure (Miller et al. 1988) was used to extract DNA from 
the cultured cells. 
The cells were pelleted by centrifugation at 1000xg for 3 min followed by 
removal of the culture media. The cell pellet was washed with 10ml PBS 
(Phosphate Buffer Saline) before it was resuspended in 3ml of nuclei lysis 
buffer (10mM Tris-HCl, 400mM NaCl, 2mM EDTA, pH 8.2). 0.2ml of 10% 
SDS and 0.5ml of protease K solution (2mg/ml Protease K in 1% SDS and 
2mM EDTA) were added to the cell lysates and then incubated overnight at 
Û&$IWHUWKHGLJHVWLRQZDVFRPSOHWHPORIVDWXUDWHG1D&OVROXWLRQa0
was added followed by 15 seconds of vigorous shaking before centrifugation at 
2500rpm for 15 min. The supernatant containing the DNA was transferred to a 
new tube. Exactly two volumes of absolute ethanol was added and the tube was 
inverted several times. The precipitated DNA strands were removed to 100-
200µl of TE buffer (10mM Tris-HCl, 0.2mM EDTA, pH 7.5). The DNA was 
DOORZHGWRGLVVROYHIRUKRXUVDWÛ&WKHQVWRUHGDWÛ& 
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3.2.2 Phenol/chloroform extraction of DNA 
An equal volume of phenol/chloroform (1:1, v:v) was added to the DNA 
sample. The sample was then centrifuged in a microfuge at 16000 x g for 5 
min. The aqueous phase was removed to a new tube and an equal volume of 
chloroform was added. The sample was then centrifuged at 1600 x g for 5 min. 
The upper aqueous phase was removed to a new tube after the centrifugation.  
1µl glycogen (20mg/ml) and 10% 3M NaAc, pH 5.5 was added prior to the 
addition of two volumes of absolute ethanol. After incubation at -ÛC for 30 
minutes, the sample was centrifuged at 16000 x g for 10 minutes. The 
supernatant was discarded and the pellet was washed with 70% ethanol.  The 
pellet was left to air dry then dissolved in 10µl of distilled water. 
3.3 Electrophoresis 
Agarose gels (1%, 2%, 3% or 4% w:v) were prepared using agarose powder 
and 1x TAE buffer. Ethidium bromide (0.5µg/ml) was added to the gel to 
enable visualization of the DNA with UV light. Electrophoresis was carried out 
in 1% TAE buffer at 5V/cm until the required resolution was achieved. 
3.4 Haplotyping of the cell lines 
PCR was carried out on the genomic DNA of the lymphoblastoid cells to 
amplify the SSLP or p13-E11 regions. For the primer pairs and the conditions 
used for each PCR refer to Table 3.3. 
3.5 Subcloning 
Subcloning of the SSLP PCR products was carried out using the CloneSmart 
Blunt Cloning Kit (Cambridge Bioscience #40856-1): 
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3.5.1 ligation 
The PCR products were purified using a GeneElute PCR Clean-Up Kit 
(#NA1020) and eluted in 30µl of distilled water. The PCR products were 
phosphorylated by treatment with 1µl T4 polynucleotide kinase (PNK) 
(Promega) and 5µl of T4 ligase buffer in total volume of 50µl. End-labeling 
the PCR product with a phosphate group is necessary to enable ligation into the 
vector. 7KH 31. WUHDWPHQW ZDV FDUULHG RXW DW Û& IRU PLQ IROORZHG E\
LQFXEDWLRQ DW Û& IRU PLQ to deactivate the enzyme. Phosphorylated 
fragments were then purified using the GeneElute PCR Clean-Up Kit in order 
to remove PNK from the solution. The presence of the PCR products in the 
elute was verified by electrophoresis at this stage. 
100-200ng of blunt and phosphorylated DNA was ligated into pSMART 
LCKan vector by following the CloneSmart Blunt Cloning Kit protocol 
(Lucigen Corporation). Each reaction was incubated at room temperature for 2 
hours. The ligase was inactivated by 15min incubation at 7Û& 
3.5.2 Transformation 
E.Cloni 10G chemically competent cells (Lucigen Corporation) were used for 
transformation. 1µl of ligations was added to the cells followed by incubation 
on ice for 30 minutes. The cells were then incubated DW Û& IRU VHFRQGV
and placed back on ice for a further 2 minutes. 960µl of room temperature 
Recovery Medium was added to the cells. The cells were then incubated at 
Û&IRUKRXULQDVKDNLQJLQFXEDWRUDWUSPORIFHOOVZDVSODWHGRQ
a nutrient agar plate containing kanomycin (30µg/ml) and incubated over night 
DWÛ& 
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3.6 Selection of positive clones 
3.6.1 Colony PCR 
Colony PCR was carried out to select for the clones carrying the correct insert. 
A small amount of a colony was added to 12µl of sterile distilled water with 
12.5µl of BIOMIX Red (Bioline) and appropriate primers (2µM). Standard 
3&5 FRQGLWLRQV FRQVLVWHG RI  F\FOHV RI GHQDWXUDWLRQ DW Û& IRU VHF
annealing at different temperatures depending on the primer pair (refer to Table 
3.3) for 30sec, elongaWLRQDWÛ&IRUVHF.E7KHFORQHVFDUU\LQJWKHFRUUHFW
sized insert were selected after analysis by electrophoresis. 
3.6.2 DNA purification - Plasmid DNA miniprep 
The positive clones were grown over night in growth media containing 
kanomycine. The Gene Elute plasmid Miniprep kit (Sigma) was used. The 
manufactXUHU¶V protocol was followed except that the DNA was eluted from 
the purification columns in 50µl sterile distilled water. 
3.6.3 Restriction digestion 
The plasmid DNA minipreps were further verified as positive clones by EcoR1 
digestion. DNA was incubated with 10µl of EcoR1 solution containing 1µl 
EcoR1 and 2µl buffer H (Promega #R6011 DW Û& IRUKRXUV. The clones 
containing the right sized fragments were sequenced. 
3.7 Sequencing 
50ng of DNA was used per sequencing reaction. Big dye (diluted 1:12 with 5 x 
sequencing buffer) and appropriate primers (10pM) were used to amplify 
cloned region. The cycling conditions were as follows: 5min DWÛ&IROORZHG 
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E\  F\FOHV RI Û& IRU VHF 50ÛC for 20sec and Û& IRU PLQ The 
products were purified using CleanSeq and sent to Durham sequencing. Editing 
of sequence traces was carried out using Sequencher 4.9. 
 
3.8 Chromatin Immunoprecipitation (ChIP) 
ChIP procedure was carried out using EZ-0DJQD&K,3$ (Millipore). All 
the reagents used were provided by the kit unless otherwise stated. 
3.8.1 Crosslinking of chromatin 
Patients and control lymphocytes were cultured and counted using a 
haemocytometer. Approximately 1 x 107 cells were used per reaction. 
Formaldehyde solution (38%) (Sigma 05-690) was added to a final 
concentration of 0.4% and the sample was incubated at room temperature for 
10 min on a rotator.  1M glycine was added to a final concentration of 125mM 
to quench unreacted formaldehyde and stop over-crosslinking. The sample was 
inverted to mix and incubated at room temperature for a further 5 min. The 
sample was kept on ice from this point on. After centrifugation at 800 x g for 5 
PLQ DW Û& WKH VXSHUQDWDQW ZDV UHPRYHG and the pellet was resuspended in 
10ml of chilled PBS and Protease inhibitor Cocktail II solution (96% 1x PBS, 
4% Protease inhibitor Cocktail II). This wash was then repeated once. The 
crosslinked cell pellets were snap frozen in liquid nitrogen and stored at -ÛC. 
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Primer name 6HTXHQFH¶-¶ Product 
size (bp) 
PCR Conditions 
Denaturation Annealing Elongation No. of 
cycles Temp. 
Û& 
Time Temp. 
Û& 
Time Temp. 
Û& 
Time 
D4F104S F1 CCCAGTTACTGTTCTGGGTGA 
500 98 10sec 60 5sec 72 30sec 30 
D4F104S R1 GAAAGCCCCCTGTGGGAG 
SSLP F1 GGTGGAGTTCTGGTTTCAGC 
160 95 15sec 59 15sec 72 15sec 30 
SSLP R CCTGTGCTTCAGAGGCATTTG 
 
Table 3.3 Primers used for SSLP and p13-E11 amplification by PCR.  
The sequence of each primer in addition to the PCR conditions used for amplification is also shown in this Table. D4F104S primer pair was used 
for p13-E11 amplification. SSLP primer pair was used to amplify the SSLP region. 
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3.8.2 Preparation for sonication 
The crosslinked cell pellet was resuspended in 500µl of Cell Lysis Buffer 
(CLB) containing 1% Protease inhibitor Cocktail II. This was followed by 
incubation on ice for 15 min, vortexing every 5 min. The sample was then 
centrifuged at 800xg IRUPLQDWÛ&7KHVXSHUQDWDQWZDVUHPRYHGDQG WKH
pellet was resuspended in 500µl of Nuclear Lysis Buffer (NLB) containing 1% 
Protease inhibitor Cocktail II. 
3.8.3 Optimisation of the sonication conditions 
Different power settings of the sonicators in addition to different duration and 
number of pulses were tested. 10% of the samples were removed prior to the 
sonication for analysis of the unsheared DNA. During the sonication 10% 
aliquots were removed after a set number of cycles. After the sonication the 
sample volumes were made up to 50µl with ChIP elution buffer and 0.5mg of 
RNase A (Sigma #R6148) was added to each sample. This was followed by 30 
minutes incubatioQ DW Û& g Proteinase K (Qiagen) was added to each 
VDPSOHDQGLQFXEDWHGRYHUQLJKWDWÛ&WRGHQDWXUHWKHFURVVOLQNHGSURWHLQV
The DNA fragments were purified by phenol/chloroform extraction (section 
3.2.2) and analysed on a 2% gel. 
3.8.3.1 6RQLFDWLRQXVLQJ'LDJHQRGH%LRUXSWXUH 
The cross-linked sample in NLB was split equally between two 1.5ml 
eppendorf tubes as 250µl aliquots. Each sample was sonicated at high power 
for 14 cycles of sonication (30 sec on/30 sec off). The ice was changed every 5 
cycles to avoid heating of the sample. After sonication, the sample was 
centrifuged at 12000 x g IRU  PLQ DW Û&  RI WKH VXSHUQDWDQW ZDV
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removed to assess sonication efficiency by performing standard 
phenol/chloroform extraction (section 3.2.2) and electrophoresis. The 
remainder of the supernatant was divided into 50µl aliquots, each containing 
approximately 1x106 cells, which is sufficient for one immunoprecipitation. 
Aliquots were either used immediately or were snap frozen in liquid nitrogen 
and stored at -Û& 
3.8.3.2 6RQLFDWLRQXVLQJ&RYDULV6-series 
7KHVDPSOHLQ1/%ZDVWUDQVIHUUHGWRD&RYDULV7&JODVVWXEH-13mm x 
65mm (#520025). The sample was sonicated for 20 to 50 cycles (30 seconds 
on/30 second off) with the intensity ranging from 3 to 8. Duty cycle was set to 
20% with 200 cycles per burst. After the sonication the sample was transferred 
to a 1.5ml eppendorf tube and centrifuged at 12000 x g IRUPLQDWÛ&
of the supernatant was removed to analyse the sonication efficiency and the 
rest of the supernatant was aliquoted and stored as described above. 
3.8.4 Immunoprecipitation (IP) 
For each immunoprecipitation reaction 50µl of sonicated material was 
combined with 450µl of Dilution Buffer (DB) containing 2.25µl of Protease 
Inhibitor Cocktail II. 5µl was removed from one of the IPs for input control, 
which represents the total amount of chromatin in the sonicated samples before 
IP. An appropriate amount of antibody (described in section 3.8.6) and 20µl of 
fully re-suspended protein A magnetic beads were added to each IP. The IPs 
were LQFXEDWHGRYHUQLJKWDWÛ&RQDURWDWLQJZKHHO 
Protein A magnetic beads were pelleted using a magnetic separator and the 
supernatant was discarded. The beads were then washed consecutively with 
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500µl of Low Salt Immune Complex Wash Buffer, High Salt Immune 
Complex Wash Buffer, LiCl Immune Complex wash buffer and TE Buffer. 
7KH VDPSOHV ZHUH LQFXEDWHG IRU  PLQ DW Û& RQ D URWDWLQJ ZKHHO IRU HDFK
wash. 
3.8.5 Reversal of crosslinking and DNA purification  
100µl of ChIP Elution Buffer (warmed to room temperature to ensure the SDS 
was dissolved) containing Proteinase K (10µg/µl final concentration) was 
added to the washed and precipitated Protein A magnetic beads as well as the 
LQSXW FRQWURO 7KH VDPSOHV ZHUH WKHQ LQFXEDWHG IRU  KRXUV DW Û& LQ D
rotating incubator.  After incubation, the samples were incubated for a further 
PLQXWHV DW Û&EHIRUH FRROLQJGRZQ WR URRP WHPSHUDWXUH7KHPDJQHWLF
separator was used to pellet the beads and the supernatant was transferred to a 
new tube. 500µl of Bind Reagent ³$´ ZDV DGGHG WR HDFK O RI WKH
supernatant. The sample was then transferred to a spin filter in collection tube 
and centrifuged for 30 seconds at 13500 x g. The flow-through in the collection 
WXEH ZDV GLVFDUGHG DQG O RI :DVK 5HDJHQW ³%´ ZDV DGGHG Wo the spin 
filter in the collection tube. The sample was centrifuged at 13500 x g for 
30seconds. The flow-through was discarded and the spin filter column was 
centrifuged for a further 30 seconds at 13500 x g. The spin filter was then 
transferred to a cleaQFROOHFWLRQWXEHDQGORI(OXWLRQ%XIIHU³&´ZDVDGGHG
directly to the centre of the spin filter membrane. The column was centrifuged 
for 30 seconds at 13500 x g. The purified DNA was then either used 
immediately for qPCR analysis or stored at -Û& 
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3.8.6 Antibodies used for ChIP 
Control antibodies, normal Rabbit IgG and H3Ac antibody were supplied by 
the EZ-Magna ChIP A kit and 5µg of each was used for each IP. Other 
antibodies used are listed in Table 3.4. 
Antibody Source Cat no. Lot no. 
Amount used per 
IP (µg) 
H3K4me2 Millipore 07-030 DAM1570816 4 
H3K9me3 Millipore 17-625 
DAM1595626 
DAM1682222 
4 
H3K9me3 Diagenode pAb-013-050 001 2.4 or 4.8 
H3K27me3 Millipore 17-622 DAM1647850 4 
 
Table 3.4 Test antibodies used in this study. 
 
3.9 Detection by quantitative real-time PCR (qPCR) 
Real-time PCR was used to quantify enrichment levels for different histone 
modifications using the purified DNA obtained by ChIP. All qPCR 
experiments in this study were carried out on a Corbett Rotor-Gene 6000 (on 
standard settings) and the results were analysed using Rotor-Gene 6000 
Software 7.1. The threshold value was calculated using the instrument-specific 
algorithm, which was carried out by the software after each run. All qPCRs 
were run in triplicates (duplicates at primer optimization stage) and the mean 
value from the triplicates was used in calculations and to create the standard 
curves after each run. SYBR green was used as the method of detection in this 
VWXG\0D[LPD6<%5*UHHQ52;T3&50DVWHU0L[;)HUPHQtas Life 
 68 
Sciences) was used for all qPCR experiments. The typical qPCR conditions 
XVHGZHUHUHFRPPHQGHGE\)HUPHQWDVIRU³7ZR-VWHSF\FOLQJSURWRFRO´ 
 
Û&  10 minutes 
Û&  15 seconds 
Û&  60 seconds 
 
qPCR reactions were carried out in a total volume of 25µl, containing 12µl 
SYBR green master mix and 5µl of 10-fold diluted elute from ChIP 
purification columns. The appropriate amounts of forward and reverse primers 
were added for efficient and specific qPCR reaction (discussed in section 
3.9.1).  
3.9.1 Calculating the correct primer concentration for qPCR 
A primer concentration test was performed for each primer pair used in this 
study (see Table 3.5 for the full list of primers). The aim of this test was to 
identify a final primer concentration whereby the qPCR was the most efficient 
but still specific to the target sequence. The efficiency of the qPCR at different 
primer concentrations was determined by the slope of the standard curve 
produced from a set of DNA serial dilutions at different primer concentration 
(Section 3.9.2). For some primer pairs, the chromosomal specificity was tested  
by using genomic DNA from the somatic cell hybrids carrying a single human 
chromosome. 
 
40x 
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Primers were tested at four final concentrations: 0.08pM, 0.4pM, 0.8pM and 
1.2pM. Each primer concentration was tested on four 10-fold serial dilutions of 
5ng/µl genomic DNA extracted from lymphocytes according to the salting out 
procedure (Section 3.2.1). 
3.9.2 Creation of standard curve 
For each qPCR run and for each primer set, a standard curve was produced. 
Standard curves were created by serial dilution (10-fold) of genomic DNA. 
Serial dilutions covered the range of 5ng/µl to 5x10^3 ng/µl which covered the 
data range obtained from the ChIP samples. Mean Ct value from these serial 
dilutions were plotted against the DNA concentration of each sample (Figure 
3.1).  
 
Figure 3.1 An example of a standard curve using the Q-PCR primers.  
The slope in this graph is -3.38, which represents a qPCR run with less than 
100% efficiency. 
y = -3.382x + 27.255
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Plotting the standard curve shows the consistency of the relationship between 
the DNA concentration and the Ct value, it also determines the efficiency, the 
sensitivity and the reproducibility of the qPCR assay. The value of the slope of 
the line (x) defines the efficiency of the reaction. A value of -3.32 for the slope 
represents a theoretically 100% efficient qPCR as this is the number of cycles 
required for a 10-fold increase in product. A more negative value than -3.32 
represents a qPCR reaction which is less efficient than 100%, whereas a value 
less negative than -3.32 indicates a reaction operating at a greater than the 
maximum efficiency, which may suggests the presence of more DNA in the 
standard curve serial dilution than thought. 
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Primer name 6HTXHQFH¶-¶ Product size (bp) 
4qA161 F AGACCCTTGTCATGCCATTT 
196 
4qA161 R GGGCAGGTTGGGAGAC 
4qA161 F2 CTTCTGGAGACCCTTGTCAT 
191 
4qA161 R2 TGGGAGACCCCCTCTGCCGT 
4qB163 F AGACCCTTGTCATGCCATTA 
195 
4qB163 R GGGCAGGTTGGGAGAT 
alphaSYBR F GGGTGCGGGCTGACTTT 
65 
alphaSYBR R CAGCGCCACCCTTTCCT 
DIST F GAGATGCTGGAGTCAGGACCAT 
91 
DIST R AGGAGTCAGGAGCAGCAGTCA 
DXZ4 F GCCTACGTCACGCAGGAAG 
210 
DXZ4 R TATGTTTGGGCAGGAAGATCG 
GAPDH F TACTAGCGGTTTTACGGGCG 
166 
GAPDH R TCGAACAGGAGGAGCAGAGAGCGA 
LUC7L F CCACGATGGCATAAGGATAATCT 
75 
LUC7L R CATACTTTCCGTGCCCTTGTG 
Q-PCR F CCGCGTCCGTCCGTGAAA 
107 
Q-PCR R TCCGTCGCCGTCCTCGTC 
Q-PCR R2 GGGGTCCAAACGAGTCTCC  
Q-PCR F3 CACAGTCCGGCTGAGGTG 
113 
Q-PCR R3 GTGCTGTCCGAGGGTGTC 
 
Table 3.5 Sequences of all the primers used for qPCR analysis. 
 The qPCR conditions used were the same for all the primer pairs (see section 
3.9). 
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3.10 Data analysis and normalization of ChIP-qPCR data 
3.10.1 Percent input method 
This method represents the ChIP-qPCR results of the IPs as a percentage of the 
total amount of chromatin that was present before the immunoprecipitation 
step. 
)LUVWO\ WKH¨&WEHWZHHQ WKH ,3VDPSOHVDQG WKHLQSXWVDPSOHZDVFDOFXODWHG
The input Ct value was corrected before the subtraction because the input 
sample represented one hundredth of the total chromatin in the IP samples 
before immunoselection. A 10-fold increase in product is represented as -3.32 
cycles when the reaction has 100% efficiency. Hence a 100-fold increase in 
products must be represented by -6.64 cycles. 
Corrected input Ct value = Ct(input) ± 6.64 
Since majority of the qPCR reactions carried out in this study showed less than 
100% efficiency, a specific correction value was calculated for each primer 
pair (Section 3.3). 
dCt = Ct(IP) ± corrected input Ct value 
Then, the %input value was calculated separately for each of the 3 replicates of 
an IP sample. 
%input = 2(dCt) 
The %input value of the triplicates was averaged. The data was then corrected 
for any background signals indicated in the no template control (NTC). 
Av %input ± Av %input NTC 
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The standard deviation between the triplicate %input values for each IP was 
calculated using Microsoft Excel software. The standard error was then 
calculated from the standard deviation.  
SE = SDEV/(3) 
This value indicated the standard error of the average taken from the triplicates 
for each IP. 
3.10.2 Normalization to a reference gene - GAPDH 
All the qPCR data obtained from different primers were normalized to GAPDH 
ChIP-qPCR results. In the concept of ChIP-qPCR data, this method represents 
the histone enrichment in the target regions relative to the histone enrichment 
at the GAPDH region. As GAPDH is a housekeeping gene and therefore 
should be expressed in all cell lines Hence, theoretically, the chromatin 
arrangements at this region should be euchromatic and similar in all the cells. 
This method enables the direct comparison of the histone enrichment levels at 
different regions of the genome in a cell line or a number of different cell lines. 
GAPDH normalisation also corrects for the experimental variation between 
separate ChIP experiments. 
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4. Results 
 
4.1 Haplotyping of BN cell line 
The BN lymphoblastoid cell line was provided by Dr. Cristina Tufarelli. This 
cell line was prevLRXVO\ XVHG DV D FRQWURO E\ 'U 7XIDUHOOLH¶V UHVHDUFK JURXS
and thought to potentially be a suitable control cell line for FSHD. To 
determine whether the BN cell line was a suitable FSHD control the haplotype 
of this cell line at the 4q35 allele had to be determined. Ideally, an FSHD 
FRQWURO FHOO OLQH VKRXOG FRQWDLQ WKH GLVHDVH ³SHUPLVVLYH´ KDSORW\SH T$
on at least one of the 4q alleles. In order to determine the haplotype of the BN 
cell line at the FSHD locus, the SSLP and p13-E11 regions were amplified and 
sequenced. 
The SSLP region was amplified by PCR and cloned in a sequencing vector and 
11 positive clones were sequenced. The p13-E11 PCR products were 
sequenced directly. The sequencing results were analysed and haplotyped 
according to Lemmers et al (2010). Only four haplotypes are expected within 
each cell line (two from the 4q and 2 from the 10q allele). Due to the identical 
sequence variants between certain haplotypes at the SSLP and the p13-E11 
region, some haplotypes cannot be distinguished using the sequencing data 
from these two regions alone (see Table 4.1). Hence, the sequencing data for 
the BN cell line indicated the presence of 2 possible haplotypes for the 10q 
allele: 10qA166 (the sequencing did not reach far enough to distinguish 
between a, b and the c variants of 10qA166 haplotype) or 10qA166Ha and 4 
possible haplotypes for the 4q: 4qA166, 4qA166Ha, 4qA166Hb or 4qC166H. 
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Nevertheless, it was indicated that the BN cell line does not have a 4qA161 
allele. 
 
 
Table 4.1 The sequence variants within the SSLP and the p13-E11 regions.  
Only the haplotypes discussed in section 4.1 are included in this table. The 
disease-permissive allele, 4qA161, is shown in the first row and the possible 4q 
and 10q haplotypes for the BN cell line are shown in the remaining rows. The 
table was adapted from Joanne Pollington. 
 
In order to ensure that no preferential amplification of one allele had occurred a 
PstI digestion was carried out on the p13-E11 PCR products from the BN cell 
line, along with a previously haplotyped lymphoblastoid cell line (GM16348) 
used as positive control for the digestion. There is an A/G variant within the 
p13-E11 region that distinguishes between the 10qA166/4qA166 and 
4qA161/4qB163 haplotypes (see Table 4.1 position 4592). PstI digestion of 
10qA166 and 4qA166 alleles produces 4 fragments (266bp, 183bp, 39bp and 
35bp). Whereas, Pst1 digestion of 4qA161/4qB163 alleles results in only two 
fragments (488bp and 35bp). 
HAPLOTYPE
C A 1 A C A 2 G/ T C T1 C T2 C T3 8 bp C
G
T
C
C
T
A
G
C
T
T
C
A
G
T
G
T
A
G
A
T
C
T
G
A
T
A
C
G
C C HR OM OSOM E
D ISTA L 
A / B
4A161 10 A 10 G 5 1 6 X C T C A C T A T T G T T T A G 4 A
4A166 9 A 8 T 5 1 7 ܂ G C T G T C G G A A T G T A G 4 A
4A166Ha 9 A 8 T 5 1 7 ܂ G C T G T C G G A A T G T A G 4 A
4A166Hb 9 A 8 T 5 1 7 ܂ G C T G T C G G A A T G T A G 4 A
4C166H 9 A 8 T 5 1 7 ܂ G C T G T C G G A A T G T A G 4 C
10A166Ha 9 A 8 T 5 1 7 ܂ G C T G T C G G A A T G T A G 10 A
10A166a 9 A 8 T 5 1 7 ܂ G C T G T C G G A A T G T A G 10 A
10A166b 9 A 8 T 5 1 7 ܂ G C T G T C G G A A C G T A G 10 A
10A166c 9 A 8 T 5 1 7 ܂ G C T G T C G G A A T G T C G 10 A
Position in 
AF117653 15
51
15
71
15
73
15
95
15
97
16
19
16
23
16
44
44
09
44
99
45
19
45
30
45
34
45
76
45
92
46
43
46
66
46
74
47
17
47
54
47
61
47
90
47
96
SSLP D4F104S1 (p13-E11)
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The results of the PstI digestion of p13-E11 PCR products from the BN cell 
line and the control (GM16348) is shown in Figure 4.1. The control displayed 
3 bands representing the 488bp fragments corresponding to 4qA161/4qB163 
and the 266bp and 183bp fragments corresponding to 10qA166/4qA166. The 
35bp and 39bp fragments were below the resolution of the agarose gel 
electrophoresis under the conditions used. This was in agreement with the 
known haplotypes assigned to GM16348. The digestion results from the BN 
cell line only displayed the 266bp and 183bp fragments corresponding to 
10qA166/4qA166. This supports the conclusion form the SSLP data that the 
BN cell line does not carry the 4qA161 haplotype. Hence there was a concern 
that the BN cell line was not a suitable control for FSHD and therefore other 
control cell lines were obtained. 
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Figure 4.1 PstI digestion of the p13-E11 region.  
PstI digestion was done on the PCR products from a FSHD lymphoblastoid 
cell line carrying the permissive 4qA161 haplotype (GM16348) and the PCR 
product from the BN cell line. Three bands at 488bp, 266bp and 183bp were 
produced from digestion of the p13-E11 of the GM16348. The digestion of the 
p13-E11 region of the BN cell lines resulted in two bands at 266bp and 183bp 
(arrows). Absence of the band at 488bp indicated that this cell line does not 
carry a 4qA161 or 4qB163 allele. 
 
4.2 qPCR optimisation 
As explained in section 1.5.1, the primer specificity to the region of interest is 
crucial when using SYBR green as the method of detection for qPCR analysis. 
In this section, the optimisation of the qPCRs used in the subsequent ChIP 
assay is described. The aim of the qPCR optimisation was to determine 
conditions that enable efficient, sensitive and the reproducible PCRs. 
4.2.1 Primer concentration optimisation 
In addition to the primer sequence, which is the most important factor in 
primer specificity, the final concentration of the primers in the PCR reaction is 
also important. Having excessive amount of primers in the reaction increases 
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the level of non-specific binding by the primers. Therefore, each primer pair 
used in this study was first tested in a primer concentration titration assay to 
determine the lowest final primer concentration without compromising the 
qPCR efficiency. The qPCR efficiency was measured by the quality of the 
standard curve obtained (section 3.9.2). 
The titration assay consisted of testing four different primer concentrations 
against three 10-fold dilutions of the template DNA. The four final primer 
concentrations used were 80nM, 0.4µM, 0.8µM and 1.2µM. A melt curve was 
obtained after each qPCR run to check for primer dimers. The 80nM 
concentration proved to be inefficient with low reproducibility for most 
primers (Figure 4.2). However, 0.4µM, 0.8µM and 1.2µM final primer 
concentrations usually gave very similar results to each other. Some primer 
pairs, especially GAPDH, did not work very well at 0.4µM (Figure 4.2A). In 
addition, 0.4µM final concentration gave inconsistent results for other primer 
pairs such as Q-PCR (Figure 4.2C, D). 
Therefore, 0.8µM final concentration was chosen for all the primer pairs used 
in this study, as this final concentration proved to be the lowest concentration 
that produced efficient and reproducible PCR reactions for all primer pairs. 
One standard final concentration was chosen for all primer pairs because 
choosing different concentration for each primer pair introduces an additional 
variable step in the ChIP-qPCR assay. In addition, changing the primer 
concentration may mask the biological differences between the samples when 
comparing the ChIP-qPCR results of different regions in the genome. 
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Figure 4.2 Primer concentration titration assay.  
Legend on next page 
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Data from qPCRs with four different primer concentrations on three 10-fold 
dilutions of the template DNA. The four final concentration used were 80nM 
(green), 0.4µM (red), 0.8µM (blue) and 1.2µM (not shown on these graphs). 
The diagram shows the qPCR run and the melt curve for four different primer 
pairs. Black lines represent the no template control at the three different primer 
concentrations. No primer dimers formation was observed on any of the melt 
curves. (A) Primer concentration titration test on GAPDH primer pair. GAPDH 
primer pair did not work efficiently at 80nM or 0.4µM. (B) Primer 
concentration titration test on DXZ4 primer pair. DXZ4 primer pair produced 
an efficient qPCR at all three primer concentrations. (C, D) Primer 
concentration titration test on Q-PCR primer pair. (C) Q-PCR primer pair did 
not work efficiently at 80nM. Both the 0.4µM and 0.8µM primer 
concentrations produced efficient and very similar results. (D) Results obtained 
for Q-PCR primer pair at 0.4µM were not consistent as they showed much less 
efficiency compared to the first test (C). (E) Primer concentration titration test 
on rDNA primer pair. rDNA primer pair produced an efficient qPCR at all 
three primer concentrations. However, amplification in no template control 
(black) was observed every time these primers were used and so they were not 
used for the remainder of this project. 
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4.2.2 Primer specificity 
The specificity of some of the primer pairs to their target sequences was tested 
by using somatic cell hybrids containing only one or a limited number of 
human chromosomes. From these experiments it was concluded that the 
Q-PCR and 4qA161 primers used by Zeng et al (2009) were not as specific as 
suggested by these authors. 
 
 
 
Figure 4.3 A schematic diagram of the Q-PCR and the 4qA161 
amplification regions.  
Diagram shows the 4q allele and a single D4Z4 repeat. PCR products for Q-
PCR and 4qA161 primer pairs are shown with black bars. Figure modified 
from Zeng et al (2009). 
 
4.2.2.1 Q-PCR primer pair 
The Q-PCR primer pair sequences were obtained from Zeng et al. (2009). This 
primer pair amplifies a 107bp region within the D4Z4 repeats that overlaps 
with the start of the DUX4 ORF (Figure 4.3). Zeng et al. (2009) reported that 
this primer pair are specific to the D4Z4 repeats on chromosomes 4q and 10q. 
They showed this using (end state) PCR on DNA from a number of mono-
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chromosomal somatic cell hybrids (2009). In the current study, the specificity 
of the Q-PCR primer pair to 4q and 10q was tested using qPCR and genomic 
DNA from a FSHD lymphoblastoid cell line (GM18207) as positive control 
and five different somatic cell hybrids containing specific human 
chromosome(s): HHW416 (chromosome 4), GM11688 (chromosome 4), CY7 
(chromosomes 10, 12 and 16), GM10479A  (chromosome 14) and GM11418A 
(chromosome 15). Somatic cell hybrids containing acrocentric chromosomes 
were used because D4Z4-like repeats are known to be present on these 
chromosomes (Lyle et al. 1995). GM10479A and GM11418A were used as 
negative controls as they contain chromosomes 14 and 15, respectively. Details 
of the somatic cell hybrids used in this study are provided in Table 3.2. The 
primers were tested on 10-fold dilutions of DNA from the selected cell lines. A 
melt curve was produced after each run to investigate the presence of any 
primer dimers or amplification of alternative products in the samples. 
Using a Û& DQQHDOLQJ WHPSHUDWXUH amplification was observed in the 
chromosome 4 and chromosome 10 hybrids (Figure 4.4).  GM18207 produced 
the lowest Ct values, which is to be expected as this cell line contains a full set 
of chromosomes and therefore many target sequences for the Q-PCR primer 
pair. The Ct values from HHW416, which carries only human chromosome 4, 
were similar to the Ct values from GM18207. However, amplification also 
occurred in the hybrids containing only chromosome 14 or 15, indicating non-
specific amplification (Figure 4.4). Increasing the annealing temperature did 
not improve the specificity of this primer pair (Figure 4.4). The melt curves 
showed one peak for all the samples. This indicated formation of a product in 
the negative controls with similar size and C/G content to the product from the 
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positive controls. This non-specific binding was not due to excess of primers, 
since lowering the primer concentration to 0.4µM did not reduce amplification 
from the negative controls. The Ct values from the negative controls were 
higher than that of GM18207 and HHW416. Higher Ct value can indicate 
lower amount of template or target sequence. This is consistent with the 
Q-PCR primer pair preferential amplification from 4q and 10q repeats. 
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Figure 4.4 Specificity of Q-PCR primers to 4q and 10q at different 
annealing temperatures.  
Legend on next page 
 
 
 
 
 85 
Q-PCR primers were tested on four 10-fold dilutions of DNA from a human 
lymphoblastoid cell line (GM18207) carrying a complete set of chromosomes 
(46XY) and DNA from four different somatic cell hybrid. The somatic cell 
hybrids with human chromosome/s (in brackets) are indicated. The average Ct 
values were plotted against their relevant DNA concentration to produce the 
graphs on the left. The error bars represent the standard error of the triplicate 
&WYDOXHV7KHPHOWFXUYHVREWDLQHGDWÛ&DQGÛ&are also shown. Raising 
the annealing temperature did not improve the specificity of the Q-PCR primer 
pair, as amplification was still observed in all the negative controls. The Ct 
values of all samples increased as the annealing temperature increased, 
indicating less efficient amplification during these qPCR runs at higher 
WHPSHUDWXUHV WKDQ Û& The melt curves show formation of a single peak 
indicating that the products from the negative controls have a similar size and 
C/G content to the product from the positive controls. 
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To investigate whether the Q-PCR primer pair show tendency to target 4q over 
the other sites, the qPCR products after a full qPCR run were digested with 
XapI restriction digest. The Q-PCR amplification region contains a C/G 
polymorphism that can determine whether the amplicons are from 4q (C 
variant) or 10q (G variant) (Zeng et al. 2009). A XapI digestion site is situated 
at the site of this polymorphism. Hence, XapI digestion can be used to 
investigate whether the majority of the Q-PCR amplification is from 4q rather 
than other regions. XapI digestion of the Q-PCR products from 4q would be 
expected to produce an 88bp and a 19bp fragment. Q-PCR amplicons from 10q 
and other chromosomes do not contain a XapI site and therefore no digestion is 
expected. XapI digestion of the qPCR products from a 46XY lymphoblastoid 
cell line (GM17939) and the mono-chromosomal somatic cell hybrid 
(HHW416) is shown in Figure 4.5. Genomic DNA from HHW416 was used as 
a positive control for XapI digestion, since all Q-PCR amplifications from this 
template are expected to be from chromosome 4q. However, the Q-PCR 
products from HHW416 were only partially digested (Figure 4.5), indicating 
the presence of non-4q amplicons. XapI digestion was negative for the sample 
where the genomic DNA from GM17939 (46XY) was used as template (Figure 
4.5). This indicated that the majority of the qPCR products amplified by the Q-
PCR primers were not from the 4q repeats. 
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Figure 4.5 XapI digestion of qPCR products with Q-PCR primers. 
qPCR was carried out on genomic DNA obtained from a patient 
lymphoblastoid cell line, GM17939 (46XY), and a somatic cell hybrid 
(HHW416) carrying human chromosome 4. XapI did not digest Q-PCR 
products from GM17939. Q-PCR products from HHW416 were only partially 
digested by XapI. 
 
4.2.2.2 Alternative Q-PCR primers 
An alternative Q-PCR reverse primer sequence was designed (Q-PCR R2) and 
tested for specificity to the 4q allele (Q-PCR.2 primer pair) (Figure 4.6A). 
High levels of amplification were observed in all the samples at both annealing 
temperatures tested. However, the melt curve showed formation of a different 
product in the mono-chromosomal somatic cell hybrids carrying chromosomes 
14 and 15 to the cells carrying 4 or 10. Interestingly, the melt curve peak from 
the FSHD lymphoblastoid cell line (46XX) grouped with the peak observed for 
hybrid cell lines with chromosomes 4 and 10 (Figure 4.6A). It was concluded 
that this primer pair showed a tendency to amplify D4Z4 repeats on 
chromosome 4 and 10 over other regions. Similar results were observed when 
both forward and reverse primer sequences were altered (Q-PCR.3 primer pair) 
(Figure 4.6B). 
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Figure 4.6 Specificity of the Q-PCR.2 and Q-PCR.3 primer pairs.  
Legend on next page 
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The primer pairs were tested on four 10-fold dilutions of DNA from a human 
lymphoblastoid cell line (GM16352) carrying a complete set of chromosomes 
(46XX) and DNA from four different mono-chromosomal somatic cell 
hybrids. The consequent melt curve from each qPCR run is shown on the left. 
(A) Specificity of the Q-PCR.2 primer pair (Q-PCR F and Q-PCR R2). High 
levels of amplification were observed in all the samples at both annealing 
temperatures tested. However, the melt curve showed formation of a different 
product from the mono-chromosomal somatic cell hybrids carrying 
chromosomes 14 and 15 to the cells carrying 4 or 10 or the lymphoblastoid cell 
line (46XX). (B) Specificity of the Q-PCR.3 primer pair (Q-PCR F3 and Q-
PCR R3). Similar results were observed for this primer pair as the old forward 
and the new reverse primer sequences. 
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4.2.2.3 Testing 4qA161 primer pair 
Zeng et al (2009) reported a qPCR primer pair that amplified a region within 
the p13-E11 region (proximal to the D4Z4 repeats) and was specific for the 
4qA161 haplotype (Figure 4.3). This primer pair was designed using sequence 
variants in the p13-E11 region that are present in the 4qA161 and not in the 
4qB163 haplotype (Figure 4.7). The specificity of this primer pair to this 
regions was tested by performing a primer concentration titration on four 10-
fold dilutions of genomic DNA from a positive and a negative control. 
Genomic DNA from a FSHD lymphoblastoid cell line containing the 4qA161 
haplotype (GM18207) was used as positive control and the genomic DNA 
from a mono-chromosomal somatic cell hybrid containing human chromosome 
4qB163 (HHW416) was used as negative control. A standard curve was 
produced after each run to investigate the efficiency of the qPCR. 
The 4qA161 primer pair did not show specificity to the target region at any 
primer concentration as shown by formation of an alternative product in the 
negative control (Figure 4.8). Since the qPCR was most efficient with primer 
concentration of 0.8µM, and less non-specific amplification was observed at 
this concentration than the higher concentrations, this was the final 
concentration chosen for this primer pair. Increasing the annealing temperature 
IURP Û& WR Û& Û& DQG Û& GLG QRW LQFUHDVH WKH VSHFLILFLW\ RI WKH
4qA161 primer pair. The specificity of these primers was also tested on DNA 
from three somatic cell hybrids carrying D4Z4-containing human acrocentric 
chromosomes. Amplification was observed in all the cell lines tested, this 
indicated that this primer pair was not specific to the 4qA161 locus (Figure 
4.8). 
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Figure 4.7 Alignment of the 4qA161 primers sequences against part of the 
p13-E11 region from five different cell lines.   
The mismatches of the primer sequences with 4qB163, 10qA166, 4qA166 and 
4qB166 haplotypes are highlighted. Sequencing data provided by Joanne 
Pollington. 
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Figure 4.8 Testing the specificity of 4qA161 primers in qPCR.  
$ T$ VSHFLILFLW\ DW Û& DQQHDOLQJ WHPSHUDWXUH $PSOLILFDWLRQ ZDV
observed in the negative control, HHW416, although with higher Ct values 
than the Ct values for the positive control, GM18207. The melt curve shows 
the formation of an alternative product in the negative control (red peak). (B) 
T$ VSHFLILFLW\ DW Û& DQQHDOLQJ WHPSHUDWXUH T$ VSHFLILFLW\ ZDV
tested on five different somatic cell hybrids as negative controls.  
Amplification was seen in all the negative controls indicating a high level of 
non-specific binding by the 4qA161 primer pair. 
 
4.2.2.4 Alternative 4qA161 primers 
A new 4qA161 primer pair was designed with slightly altered sequences 
(4qA161.2 primer pair) (Figure 4.9). This primer pair was tested for specificity 
as above, using GM18207 DNA as a positive and HHW416 DNA as a negative 
control (Figure 4.10A). Amplification was still observed for the negative 
control, although with higher Ct values than the 4qA161 primer pair, was still 
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observed, and the melt curve also indicated formation of an alternative product 
in the negative control (Figure 4.10A). 
Different combinations of primers for the 4qA161 region were then tested 
(Figure 4.10). No improvement was observed using the 4q161.3 primer pair 
(4qA161 F2 and 4qA161 R) (Figure 4.10B). The 4qA161.4 primer pair 
(4qA161 F and 4qA161 R2) also resulted in amplification in the negative 
control. However, the melt curve produced from this qPCR run did not show 
formation of the alternative product, unlike the other 4qA161 primer 
combinations (Figure 4.10C). Since the 4qA161 primers showed high non-
specificity to the 4qA161 allele, these primer pairs were not used in the ChIP-
qPCR assay. 
 
Figure 4.9 Alignment of the 4qA161.2 primers sequences against part of 
the p13-E11 region from five different cell lines.   
The miss-matches of the primers with non-4qA161 haplotypes have been 
highlighted. Sequencing data provided by Joanne Pollington. 
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Figure 4.10 Specificity of 4qA161.2, 4qA161.3 and 4qA161.4 primer pairs. 
(A) Specificity of the 4qA161.2 primer pair. Some amplification, was still 
observed in negative control, although with higher Ct values than the 4qA161 
primer pair, was observed in the negative control. The melt curve indicated 
formation of an alternative product in the negative control samples with the 
highest DNA concentration. (B) Specificity of the 4q161.3 primer pair 
(4qA161 F2 and 4qA161 R). Some level of amplification was still being 
observed in the negative control. The melt curve indicated the formation of an 
alternative product in the negative control. (C) Specificity of the 4qA161.4 
primer pair (4qA161 F and 4qA161 R2). A higher level of amplification was 
observed from the negative control. However the melt curve did not show any 
evidence of an alternative product formation in the negative control. 
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4.2.2.5 4qB163 primer pair 
This primer pair was designed using sequence variants in the p13-E11 region 
that are present in the 4qB163 haplotype but not in 4qA161 (Figure 4.11). The 
specificity of this primer pair was tested as above by performing a primer 
concentration titration on four 10-fold dilutions of genomic DNA. DNA from a 
FSHD lymphoblastoid cell line with the 4qB163 haplotype (GM17939) and 
DNA from a mono-chromosomal somatic cell hybrid containing human 
chromosome 4qB163 (HHW416) were used as positive controls. Genomic 
DNA from a FSHD lymphoblastoid cell line with the 4qA161 haplotype 
(GM18207) was used as negative control for this primer pair. A standard curve 
was produced after each run to investigate the efficiency of the qPCR. 
The 4qB163 primers were most efficient at 0.8µM final concentration (Figure 
4.12A). This primer pair showed specificity to the 4qB allele as it was found to 
also amplify the 4qB168 haplotype. Amplification of 4qB168 haplotype was 
not surprising as there are no mismatches between the 4qB163 R primer and 
WKLV DOOHOHV DQG WKHUH LV RQO\ RQH PLVPDWFK DW WKH ¶ HQG RI WKH T% )
primer sequence. However, some amplification was also observed for the 
4qA161 haplotype at higher DNA concentrations. To improve the specificity 
further the annealing temperature was raiseG IURP Û& WR Û& Figure 
4.12B), which resulted in a more specific amplification (Figure 4.12B). 
However, increasing the temperature did compromise the qPCR efficiency, as 
the Ct values obtained for the positive control were higher than the Ct values 
REWDLQHGDWÛ& )RUWKLVUHDVRQÛ&DQQHDOLQJWHPSHUDWXUHZDVXVHGIRUWKLV
primer pair in all the subsequent ChIP-qPCR assays. Non-specific 
amplification by 4qB163 primers was only observed in samples containing 
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5ng/µl and 0.5ng/µl of DNA. The amount of DNA recovered from ChIP was 
usually lower than these concentrations. In addition, keeping the annealing 
temperature consistent with the other qPCR analyses allowed direct 
comparison of the data obtained by 4qB163 primer with data obtained using 
the other primer pairs in this study.  
 
 
 
 
Figure 4.11 Alignment of the 4qB163 primers against part of the p13-E11 
region from five different cell lines.  
The mismatches of this primer pair with 4qA161, 4qB166, 4qA166 and 
10qA166 haplotypes have been highlighted. Sequencing data provided by 
Joanne Pollington. 
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Figure 4.12 Specificity of 4qB163 primers for the 4qB163 allele.  
$T%VSHFLILFLW\DWS0ILQDOSULPHUFRQFHQWUDWLRQDWÛ&DQQHDOLQJ
temperature. The qPCR run is shown on the left. The melt curve obtained from 
the same run is shown on the right. Some amplification is observed in the 
negative control samples (green lines) with the highest DNA concentration. 
However, the melt curve indicates the formation of a different product in the 
negative control (green) to the products formed in the positive control (blue). 
(B) Average Ct values are plotted against their relevant DNA concentration. 
The error bars represent the standard error of the triplicate Ct values. 
Amplification is observed in the negative control samples at both 5ng/µl and 
QJO'1$ZLWKDQDQQHDOLQJWHPSHUDWXUHRIÛ&5DLVLQJWKe temperature 
resulted in increase in the Ct values for the positive control (GM18207 was not 
used in this assay). No amplification was observed in the negative control with 
DQDQQHDOLQJWHPSHUDWXUHRIÛ& 
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4.3 Calculating the corrected input value 
Almost all the standard curves obtained from the different qPCR runs with 
each primer pair illustrated less than 100% efficiency (i.e. slope value was not 
3.32). Since the data analysis of the ChIP-qPCR data relied on this value to 
correct the input Ct value (section 3.9.2 and 3.10.1), a specific input correction 
value was calculated for each primer pair. At least three different standard 
curves for each specific primer pair were compared and the slope values were 
averaged and then doubled to obtain the input correction value specific for that 
primer pair. These values are shown in Table 4.1. 
 
Primer pair Average slope 
value 
SD of the average slope 
value 
Input correction 
value 
4qB163 3.46 0.0702 6.91 
alphaSYBR 3.29 0.0624 6.58 
DIST 3.31 0.168 6.63 
DXZ4 3.29 0.0982 6.58 
GAPDH 3.48 0.0906 6.96 
LUC7L 3.48 0.309 6.95 
Q-PCR 3.38 0.121 6.76 
 
Table 4.2 Average slope value and the input correction value for each of 
the primer pairs that were used in ChIP-qPCR analysis. 
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4.4 Sonication optimization 
The aim of the sonication step is to break down the chromatin into small 
fragments without damaging the DNA-binding proteins. Keeping the proteins 
intact ensures efficient co-precipitation. The size of the chromatin fragments 
has a direct effect on the resolution of the ChIP such that the smaller the 
fragments are after the sonication, the higher the resolution of the ChIP. The 
regions of DNA bound by nucleosomes show some protection from breakage 
by sonication. Therefore, the smallest fragment size obtained by sonication 
without damaging the nucleosomes is around 200bp. If the chromatin is broken 
down to 200bp fragments, when a certain region is found to be bound by a 
certain histone modification after the ChIP analysis, it can be said that this 
histone modification was most likely present in the nucleosome bound directly 
to this region. However, having the DNA fragments too small (i.e. one 
nucleosome long), may compromise amplification of the target sequence, 
which may stretch to the regions in between two nucleosomes. Hence, the aim 
was to obtain 200-700bp fragments with the majority being between 300-
500bp, approximately 2-3 nucleosomes long. A minimum size of two 
nucleosomes ensures that most target regions stay intact. Then if a particular 
histone modification is found to be associated with a particular region, it can be 
said that this modification was present either in the nucleosome directly bound 
to this region, or in one of the neighboring nucleosomes which may be ~100-
300bp away. 
To check the level of shearing of the chromatin after sonication, the samples 
were analysed by agarose gel electrophoresis after de-crosslinking. The 
sonicated samples appear as a smear on the gel indicating a range of different 
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sized DNA fragments within the samples. For this study, two sonicators of 
different makes and models were compared for their efficiency to shear the 
chromatin with less damage to the DNA binding proteins: 
4.4&RYDULV6-series 
Originally the sonicating conditions recommended by Covaris were used for 
chromatin shearing. Sonicator conditions were set to duty cycle of 20% with 
200 bursts at intensity 8 for 30 continuous 60sec cycles. The chromatin was 
sheared very efficiently to 300-700bp fragments. However, there were some 
concerns about the increase of sample temperature that occurred during the 
course of sonication, which may have resulted in damaging the protein-DNA 
complexes. Hence, 30sec intervals between each 30sec burst were introduced. 
As the sample still increased in temperature, the intensity of the sonicator was 
reduced to 5.  
The sonicator conditions were set to duty cycle of 20% with 200 bursts at 
intensity 5 for 40 cycles (30sec on/30sec off). Aliquots were taken out after 
cycles 15, 20, 25, 30, 35 and 40 for gel electrophoresis analysis (Figure 4.13B). 
As the desired fragment size was obtained after 30 cycles without over-heating, 
these conditions were used to obtain samples for the immunoprecipitation step. 
The result of qPCR analysis of these samples is shown in Figure 4.13D. 
4.4.2 Diagenode BiorupWXUH 
The samples were sonicated at high power for 22 cycles (30sec on/ 30sec off). 
The ice was changed every 5 cycles in order to keep the samples cool. Aliquots 
were taken out after 6, 10, 14, 18 and 22 cycles for gel electrophoresis analysis 
(Figure 4.13A). As the desired sized fragments were obtained after 14 cycles 
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without over heating, these conditions were used to obtain samples for 
immunoprecipitation. The result of qPCR analysis of these samples is shown in 
Figure 4.13C. 
As mentioned above, the aim of the sonication step is to break down the 
chromatins into 200-700bp fragments without damaging the DNA-binding 
proteins. The appropriate size-range was successfully obtained using both of 
the sonicators. However, there were much lower levels of DNA recovery after 
the immunoprecipitation stage from the samples sonicated with the Covaris S-
series sonicator compared to the samples from Diagenode Biorupture 200 
(Figure 4.13C, D). The qPCR results from the two ChIPs were comparable 
because the starting material (i.e. crosslinked samples) for both sonicators were 
from the same cell line and were crosslinked at the same time. In addition, the 
non-immune IgG control result is similar for both sonicated samples (Figure 
4.13C, D). As a result of this comparison, the Diagenode Biorupture 200 was 
used to prepare the chromatin for all the subsequent ChIP analyses performed 
in this study. 
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Figure 4.13 Sonication conditions optimisation.  
(A) Gel electrophoresis analysis of the sonicated material after 6, 10, 14, 18 
and 22 sonication cycles, using Diagenode Biorupture 200. (C) Gel 
electrophoresis analysis of sonicated material after 15, 20, 25, 30, 35 and 40 
sonication cycles, using Covaris S-series. (C) ChIP-qPCR analysis of the 
samples sonicated for 14 cycles with Diagenode Biorupture 200. (D) ChIP-
qPCR analysis of the samples sonicated for 30 cycles with Covaris S-series 
sonicator. The qPCR results were normalised to the input. The error bars 
represent the standard error between the triplicate qPCR reactions for each 
sample. 
 
A 
D C 
B 
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4.5 Optimisation of the ChIP protocol 
ChIP was carried out according to the EZ-0DJQD &K,3 $  NLt (Millipore 
#17-408) protocol. As mentioned above ChIP results are often subject to some 
variability (section 1.4). Hence a number of controls were chosen to indicate 
the level of variability in some of the steps. Before the addition of the 
antibodies, 10% of the sonicated material was removed as a reference sample 
(input). This indicates the amount of starting material in each sample before 
immunoprecipitation (IP) with an antibody. Rabbit IgG antibody was used as 
the negative control for the immunoprecipitation stage. Any level of DNA 
recovered from the IgG IP is counted as background signals, which indicate the 
level of non-specific binding by IgG or the protein A magnetic beads, or other 
possible contaminant. Acetylated histone H3 (H3Ac) antibody was used as the 
positive control for the ChIP protocol. H3Ac is known to be enriched in 
GAPDH gene promoter; hence H3Ac binding at the GAPDH promoter region 
was used as a positive control for the ChIP protocol. H3K4me2, H3K9me3 and 
H3K27me3 antibodies were the test antibodies used in this study. These 
histone antibodies were used in the original study by Zeng et al. (2009). 
ChIP was carried out on two control lymphoblastoid cell lines (GM16352, 
GM08729) and three FSHD lymphoblastoid cell lines (GM16348, GM17939, 
GM16351).  H3K4m2, H3K9me3 and H3K27me3 antibodies were used 
alongside the control antibodies H3Ac and rabbit IgG. The DIST and LUC7L 
primer pairs amplify two regions within human chromosome 16p13.3 flanking 
the alpha-globin gene locus and were previously reported to be negative for 
H3K4me2 occupancy in EBV-transformed cell lines after ChIP-qPCR and 
ChIP-chip analyses (De Gobbi et al. 2007). Hence, these regions were used as 
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negative controls for H3K4me2 in this study. H3K4me2 binding at the DXZ4 
region has been shown to be sex-specific, with females having higher levels of 
H3K4me2 modification at DXZ4 site than males (Chadwick 2008). DXZ4 is a 
tandem array on the X chromosome, which is similar to the D4Z4 repeats in 
C/G content. The DXZ4 primer pair was also used as positive control for 
H3K9me3 (Zeng et al. 2009). The alphaSYBR primer pair amplify a region 
within the alpha-globin promoter region, which was shown to be negative for 
H3K9me3 histone modification in the EBV-transformed cell lines. Hence, this 
region was used as negative control for H3K9me3 binding. 
The ChIP samples were analysed by qPCR and the data obtained was then 
processed according to the normalisation method described in section 2.10.  
The %input data obtained from each qPCR with a specific primer pair was then 
used to construct a column graph comparing the %input obtained from each IP. 
This graph represented the level of each histone modification studied (H3Ac, 
H3K4me2, H3K9me3 and H3K27me3) in that specific region which was 
amplified by the primer pair.  
H3K9me3, H3K27me3 and in most cases H3K4me2 %input values appeared to 
be notably higher than that of H3Ac in all genomic regions analysed. This in 
addition to positive results obtained from the negative control regions, 
alphaSYBR, DIST and LUC7L, raised the suspicion that the antibodies used in 
these ChIP analyses have some non-specific binding. Non-specificity of an 
antibody in ChIP analysis could result in immunoprecipitation of regions of the 
genome that may not have been bound by the specific protein of interest. 
Attempts were therefore made to asses the specificity of antibody binding. 
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4.5.1 H3K9me3 titration 
To investigate whether anti-H3K9me3 non-specificity was due to excessive 
amounts of the antibody in the IP samples, H3K9me3 antibody concentration 
titration was carried out on both a control and a FSHD lymphoblastoid cell line 
(Figure 4.14). Prior to this, H3K9me3 antibody was used at the manufacturer¶s 
recommended concentration of 4µg/IP. The amount of antibody was reduced 
from 4µg to 3µg, 2µg and 1µg for the titration experiment. H3Ac and rabbit 
IgG antibodies were used as positive and negative controls for the ChIP 
procedures. The data from the qPCR analyses were used to calculate the 
%input value for all the IPs (Figure 4.14). 
The data showed that reducing the amount of the antibody resulted in lowering 
of the %input value, which represents the DNA recovery after the 
immunoprecipitation step. A sharp drop in %input values was observed when 
1µg of H3K9me3 antibody was used on the FSHD sample. This was not true 
when the titration ChIP was repeated on a control cell line, where the decrease 
observed in %input value had more of a gradual decrease. The sharp drop in 
%input value observed in the FSHD sample was thought to have occurred due 
to a pipetting error, which resulted in a lower concentration of protein A 
magnetic beads in this IP compared to the other five IPs in this ChIP. 
The %input values obtained from the negative control region, alphaSYBR, 
stayed close to the %input values obtained from the DXZ4 and Q-PCR regions 
regardless of the anti-H3K9me3 concentration. It was concluded that the 
decrease in H3K9me3 antibody concentration does not result in more specific 
binding. 
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Interestingly, the same pattern of related %input values at different regions was 
seen for all anti-H3K9me3 concentrations; H3K9me3 %input value was the 
lowest at the GAPDH region and the highest at the Q-PCR region (Figure 
4.14). Maintenance of this pattern throughout the titration assay indicates that 
the H3K9me3 antibody shows some specificity to its epitope(s), which was 
maintained at different concentrations. 
The impact of the antibody concentration difference between the different IPs 
in the titration assay was undermined when the %input data was normalized to 
the GAPDH data (Figure 4.15). The %input values obtained with DXZ4, Q-
PCR and alphaSYBR were normalized to the %input value obtained with 
GAPDH. This method accounted for some of the differences in the DNA 
recovery after the immunoprecipitation stage. Note that some level of 
variability is still observed between the IPs even after the normalisation (Figure 
4.15). This highlights the importance of repeating the ChIP-qPCR analyses for 
obtaining more accurate results. 
Thus, it was concluded that as long as the data obtained for an IP is represented 
as a %input value relative to the %input value of GAPDH, it is comparable to 
the other IPs with the same antibody. Thus, GAPDH normalisation was used as 
a method to reduce the effects of the variability between different ChIP assays 
induced by the IP step. 
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Figure 4.14 Antibody titration analysis.  
Parallel ChIP assays using H3K9me3 where performed on a control 
(GM16352) and a patient (GM17939) lymphoblastoid cell line. The amount of 
H3K9me3 antibody was reduced from 4µg to 3µg, 2µg and 1µg per IP. H3Ac 
along with the GAPDH primers was used as positive control for ChIP. Rabbit 
IgG was used as negative control to indicate any background signals. 
alphaSYBR primers were used as negative control for H3K9me3 binding. The 
error bars represent the standard error between the three Ct values obtained for 
each IP. 
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Figure 4.15 GAPDH normalisation of the antibody titration analysis data. 
The %input data from DXZ4, Q-PCR and alphaSYBR was normalised to the 
%input data from GAPDH 
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4.5.2 Comparison of H3K9me3 antibodies from Diagenode and 
Millipore 
New batches of H3K9me3 antibody were obtained from Millipore (Cat #17-
625 Lot #DAM1682222) and Diagenode (Cat#pAb-013-050 Lot #001) in order 
to compare the specificity during the ChIP procedure. ChIP and qPCR were 
carried out in parallel using these new antibodies. IgG and H3Ac were used as 
negative and positive controls for this ChIP. H3K4me3 antibody (Millipore), 
which was used in all the previous ChIP assays, was also used here as a 
comparison for %input values that were obtained with the first batch of 
Millipore H3K9me3 antibody. However, both batches of antibodies failed to 
recover any significant amount of DNA, even when the ChIP experiments were 
repeated independently. The %input values obtained from H3Ac and 
H3K4me2 antibodies were similar to previous ChIP experiments, which 
indicates that there was unlikely to be a problem with the ChIP or the qPCR 
procedures. The failure to recover DNA was therefore due to problems with the 
new batches of antibodies. This problem precluded further analysis of 
H3K9me3 modification during this project. 
4.5.3 Normalisation of the ChIP-qPCR data to GAPDH 
The %input data obtained for each antibody using different primer pairs were 
combined to compare the values at different regions. The data from the two 
repeat ChIPs on each cell line showed a very similar pattern. However, there 
was a great difference between %input values, with the second ChIP having 
much lower recovery than the first ChIP. One possibility is a reduction in the 
efficiency of the antibodies in the time between the first and the second ChIP. 
However, normalisation to GAPDH made the %input values more comparable 
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between the two ChIPs. The mean of the data from the two ChIPs are presented 
in Figures 4.16 - 4.19. 
 
4.6 Result of the ChIP-qPCR analysis 
4.6.1 H3Ac 
The normalised ChIP-qPCR data for H3Ac is shown in Figure 4.16. There was 
a large variability between the cell lines regarding the H3Ac occupancy in the 
genomic regions that were analysed, with one of the control cell lines 
(GM08729) yielding the lowest levels in most regions analysed. This was 
closely followed by one of the FSHD cell lines (GM17939), which had very 
low levels of H3Ac in all regions except at DXZ4 and 4qB163. The control cell 
line (GM16352) showed very small variability in H3Ac content between 
different sites. The H3Ac content for the two remaining FSHD cell lines 
(GM16348, GM16351) were similar at DXZ4, Q-PCR and alphaSYBR sites. 
GM16348 showed a lower H3Ac content at DIST, LUC7L and 4qB163 regions 
compared to GM16351. The highest level of H3Ac was observed at the 
4qB163 region of the GM16351 cell line. This high value was obtained from 
one of the ChIP assays and was not true for the other two. This is indicated by 
the large error bar on the graph (Figure 4.16). 
Overall, there was no significant pattern observed for H3Ac histone 
modification between control and FSHD cell lines amongst the regions 
analysed. 
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Figure 4.16 ChIP-qPCR results for H3Ac histone modification.  
Data is from two control lymphoblastoid cell lines (GM16352, GM08729) and 
three FSHD lymphoblastoid cell lines (GM16348, GM17939, GM16351). The 
%input value for each region is normalised %input value of GAPDH. The error 
bars represent the standard error between the normalised data from three 
independent ChIP assays (except GM16348, where the standard error is 
obtained from two separate ChIP assays). 
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4.6.2 H3K4me2 
The normalised ChIP-qPCR data for H3K4me2 is shown in Figure 4.17. DIST 
and LUC7L regions were used as negative controls for H3K4me2 (see Section 
4.5). Our data did not show much difference in H3K4me2 occupancy at these 
two regions when compared to other sites. 
Comparing the different cell lines for the H3K4me2 levels at different genomic 
regions revealed some level of reduction in H3K4me2 occupancy at the Q-PCR 
region in FSHD patients compared to the control cell lines. This level of 
decrease was not observed in any other regions analysed, with exception to 
DXZ4. The H3K4me2 levels at DXZ4 were previously shown to be sex-
specific (Chadwick 2008). A small difference was observed between the 
H3K4me2 levels of the two controls, with the male cell line (GM08729) 
yielding lower levels of this histone modification at this site. Therefore the 
level of H3K4me2 at DXZ4 in the male FSHD cell lines (GM17939 and 
GM16351) were compared to the male control (GM08729). Similarly the 
female FSHD cell line (GM16348) was compared to the female control 
(GM16352).  The male FSHD cell lines showed a reduction in H3K4me2 
compared to the male control cell line. The female FSHD cell line did not 
follow the same pattern and did not show a reduction in H3K4me2 histone 
modification at DXZ4. However, the H3K4me2 levels at DXZ4 for this cell 
line was not consistent between the two different ChIP-qPCR assays. 
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Figure 4.17 ChIP-qPCR results for H3K4me2 histone modification.  
Data is from two control lymphoblastoid cell lines (GM16352, GM08729) and 
three FSHD lymphoblastoid cell lines (GM16348, GM17939, GM16351). The 
%input value for each region is normalised %input value of GAPDH. The error 
bars represent the standard error between the normalised data from two 
independent ChIP assays.  
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4.6.3 H3K9me3 
The normalised ChIP-qPCR data for H3K9me3 is shown in Figure 4.18.  The 
H3K9me3 ChIP-qPCR results from the second ChIP done on GM17939 were 
excluded from the final analysis. This was because the second batch of 
Millipore H3K9me3 antibody (Cat #17-625 Lot #DAM1682222) was used for 
this ChIP, which resulted negative %input values when normalised and were 
not comparable with the previous data. alphaSYBR region was used as 
negative control for H3K9me3 binding. The H3K9me3 levels obtained for 
alphaSYBR region were, in most cases, very similar to the H3K9me3 levels in 
DXZ4. This pattern was also maintained during the H3K9me3 titration 
experiment (section 4.5.1). LUC7L region showed lower H3K9me3 levels 
compared to other regions in all cell lines except for GM16351 (FSHD) where 
4qB163 contained the lowest levels of H3K9me3. This, further to the 
H3K9me3 titration assay, verifies the non-specificity of the H3K9me3 
antibody. It is possible that this H3K9me3 antibody also binds to another 
histone modification at the alphSYBR region that maybe absent from or is 
present at lower levels at the LUC7L region. This can explain the difference 
between the H3K9me3 data at alphaSYBR and LUC7L.  
 The Q-PCR region contained the highest levels of H3K9me3 in all the cell 
lines analysed. Comparing the H3K9me3 data from different cells revealed a 
decrease in H3K9me3 levels in FSHD cell lines when compared to the control 
cell lines at all the genomic regions tested. This difference was less profound 
between the control cell line, GM16352 and the FSHD cell lines at 
alphaSYBR, DIST and LUC7L regions compared to the difference observed at 
DXZ4, Q-PCR and 4qB163 regions. H3K9me3 levels for the second control 
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cell line, GM08729 were higher than those of the GM16352 control cell line at 
all the regions analysed. Consequently, all FSHD cell lines demonstrated a 
reduction in H3K9me3 at all regions compared to this control cell line. 
ChIP-qPCR was not carried out on an adequate number of control cell lines to 
enable a statistical analysis of the difference observed between the H3K9me3 
occupancy in the control and the FSHD cell lines. 
 
 
Figure 4.18 ChIP-qPCR results for H3K9me3 histone modification.  
Data is from two control lymphoblastoid cell lines (GM16352, GM08729) and 
three FSHD lymphoblastoid cell lines (GM16348, GM17939, GM16351). The 
%input value for each region is normalised %input value of GAPDH. The error 
bars represent the standard error between the normalised data from two 
independent ChIP assays (excluding GM16348 and GM17939). 
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4.6.4 H3K27me3 
The normalised ChIP-qPCR data for H3K27me3 is shown in Figure 4.19. The 
highest levels of H3K27me3 were observed at the alpha region for all the cell 
lines. The lowest levels were observed at the LUC7L region, except for the 
GM08729 control cell line where 4qB163 region had the lowest levels of 
H3K27me3.  
Comparing the H3K27me3 levels between the cell lines revealed a reduction in 
H3K27me3 levels at all the regions in FSHD cell lines compared to the control 
cell lines. H3K27me3 levels were very similar between the two control cell 
lines at all the regions except at 4qB163. The control cell line, GM08729, 
showed low levels of H3K27me3 at the 4qB163 region compared to GM16352 
(control). The H3K9me3 levels at 4qB163 for this control cell line (GM08729) 
were similar to the H3K27me3 levels for the FSHD cell lines. 
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Figure 4.19 ChIP-qPCR results for H3K27me3 histone modification.  
Data is from two control lymphoblastoid cell lines (GM16352, GM08729) and 
three FSHD lymphoblastoid cell lines (GM16348, GM17939, GM16351). The 
%input value for each region is normalised %input value of GAPDH. The error 
bars represent the standard error between the normalised data from two 
independent ChIP assays (excluding GM16348). 
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5. Discussion 
 
5.1 Q-PCR primer pair specificity to 4q and 10q 
The Q-PCR primer pair was designed for qPCR analysis and was shown to 
amplify products exclusively from chromosome 4 and 10 and not from any 
other chromosome by Zeng et al. (2009). DNA from somatic cell hybrids 
carrying individual human chromosomes was used to verify the specificity of 
this primer pair (Zeng et al. 2009). However, in this study, the specificity of 
these primers to chromosome 4 and 10 was not confirmed.  
The somatic cell hybrids used in this study were obtained from the same 
company (Coriell Repositories) as the cells used by Zeng et al. (2009), three of 
which were the same cell lines (GM11687, 11688 and 10479, carrying 
chromosomes 4, 10 and 14 respectively). Chromosomes 14 and 15 are two of 
the chromosomes that are known to contain D4Z4-like repeats and for that 
reason, the Q-PCR primer pair was tested on cell hybrids carrying these two 
chromosomes (GM10479 and 11418A) as negative controls. Amplification of a 
product was detected from chromosomes 14 and 15, as well as 4 and 10, which 
suggests that this primer pair was not as specific as suggested by Zeng et al. 
(2009), at least not under the qPCR conditions used in this study. Zeng et al. 
(2009) fail to provide any PCR or qPCR conditions in the published article. 
It was speculated that the Q-PCR primer pair show some tendency to 
chromosome 4 over the other chromosomes. This was based on the observation 
that the Ct values from the hybrid cell line carrying chromosome 4 (HHW416) 
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were very close to the Ct values from the human lymphoblastoid cell line 
containing all chromosomes (GM18207) (Figure 4.4).  
5.1.1 XapI digestion of the region amplified by Q-PCR primer pair 
The region amplified by the Q-PCR primer pair contains a C/G variant that 
allows distinction of 4q-derived products from 10q-derived products (Zeng et 
al. 2009). This C/G variant creates a XapI site on chromosome 4 (C variant), 
which is absent on chromosome 10 (G variant). 
In order to investigate whether the majority of the qPCR products amplified by 
the Q-PCR primer pair were from chromosome 4, XapI digestion was carried 
out. There was no digestion of the PCR products from the human 
lymphoblastoid cell line (GM17939), indicating a majority presence of non-4q-
derived products. Partial digestion of the positive control (HHW416, carrying 
chromosome 4) indicated the presence of some non-4q-derived products 
(Figure 4.5). Since the HHW416 hybrid cell line is advertised as a mono-
chromosomal somatic cell hybrid carrying human chromosome 4 only, it is 
possible that the Q-PCR primers may amplify a region within the Chinese 
hamster genome. However, it is also likely that this somatic cell hybrid also 
contains parts of other human chromosomes.  
GM11687 is another mono-chromosomal somatic cell hybrid carrying 
chromosome 4 only. The Q-PCR primer pair was not tested on the DNA from 
the GM11687 cell line. The XapI digestion can be repeated on the qPCR 
products from this cell line to further investigate the specificity of the Q-PCR 
primer pair. 
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5.1.2 Alternative Q-PCR primer sequences 
The Q-PCR primer sequences were altered in order to increase the specificity 
of amplification of the D4Z4 repeats on chromosome 4q. However, 
amplification was still detected from chromosomes 14 and 15, which resulted 
in the formation of different products to those formed from chromosomes 4 
and 10. The different products could be distinguished from the consequent melt 
curves produced from these samples. The melt curve obtained from the human 
lymphoblastoid cell line (GM16352) closely resembled the melt curve obtained 
from chromosomes 4 and 10 (Figure 4.6). It can therefore be concluded that 
these primer pairs show higher affinity to the D4Z4 repeats on 4q and 10q over 
chromosomes 14 and 15. Further analysis using other mono-chromosomal 
somatic cell hybrids is needed to conclude that these primer pairs always 
preferentially amplify regions from chromosome 4 and 10. 
5.2 Antibody specificity 
All the antibodies in this study were used DWWKHPDQXIDFWXUHU¶VUHFRPPHQGHG
final concentration for ChIP analysis. The concentration of the antibody used 
in the ChIP procedure should be as such that it is enough to saturate all target 
sites but not too in excess to cause non-specific binding. Low amounts of 
antibody used in IP can cause preferential binding to some regions over others 
and hence affect the ChIP outcome. H3K9me3, H3K27me3 and in most cases 
H3K4me2 %input values appeared to be notably higher than that of the control 
antibody H3Ac in all genomic regions analysed. This, in addition to positive 
results obtained from the negative control regions, alphaSYBR, DIST and 
Luc7L, raised the suspicion that the antibodies used in these ChIP analyses had 
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some non-specific binding. Hence, the H3K9me3 titration assay was carried 
out. 
The titration results showed that reducing the amount of the antibody resulted 
in lowering of the %input value, which represents the DNA recovery after the 
immunoprecipitation step (Figure 4.14). At first glance the results from the 
H3K9me3 antibody titration was to be expected, but one can argue that if the 
H3K9me3 antibody was highly specific to its epitope, raising the concentration 
should not have resulted in continuous increase in binding and hence DNA 
recovery. In theory, the increase in binding should stop once all target sites are 
saturated. Assuming the saturation step was at some stage before the 
PDQXIDFWXUHU¶V UHFRPPHQGHGDQWibody concentration, our results suggest that 
the H3K9me3 antibody (Millipore) is not very specific to its epitope. 
 In the support of this conclusion, the %input values obtained from the negative 
control region, alpha, stayed close to the %input values obtained from the 
DXZ4 and Q-PCR regions regardless of the H3K9me3 antibody concentration. 
This also indicated that the non-specificity of the H3k9me3 antibody was not 
due to excess of this antibody in each IP. 
Interestingly, the pattern obtained from the related %input values at different 
regions was maintained throughout the change in the anti-H3K9me3 
concentration (Figure 4.14). Maintenance of this pattern throughout the 
titration assay indicates that the H3K9me3 antibody shows specificity to one or 
a few other epitopes that is maintained at different concentrations. 
A study in 2004 (Perez-Burgos et al. 2004) investigated the specificity of 
commercially available methyl-lysine histone antibodies. This study 
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investigated the cross-reactivities between these antibodies and other methyl-
lysine histone modifications by peptide spotting analysis (dot blots). Their data 
indicated significant discrepancies in the specificity and avidity of the available 
methyl-lysine histone antibodies (Perez-Burgos et al. 2004). The main focus of 
the study was on antibodies against methylated H3K9 and H3K27. This is 
because the lysine 9 and lysine 27 positions on histone H3 are embedded 
ZLWKLQ WKH VDPH DPLQR DFLG VHTXHQFH ³-ARKS-´ WKHUHIRUH DOORZLQJ IRU
considerable cross-reactivities of respective methyl-lysine histone antibodies 
(Perez-Burgos et al. 2004). The affinity of these antibodies towards different 
linear peptides was also determined by using a serial dilution of these peptides. 
The H3K9me2 antibody from Upstate Biotech (now supplying to Millipore) 
was found to show a high affinity to H3K9me2, but also show minor cross-
reactivities with H3K4me2 and H3K27me3. This was different from the 
H3K9me2 antibody from Abcam, which showed minor cross-specificity to 
H3K36me2, H4K20 and H3K27me3 (Perez-Burgos et al. 2004). It was proven 
that these cross-reactivities could be minimised by using a 2-branched peptide 
that encompasses the H3K9me2 position by five amino acids on either side 
(Perez-Burgos et al. 2004). 
According to the Millipore product information, the H3K27me3 antibody is a 
2-branched antibody. However, this is not specified for H3K9me3 or 
H3K4me2 antibodies. Therefore, it is possible that the H3K9me3 and 
H3K4me2 antibodies used in this study have some cross-reactivities with other 
histone modifications. Nevertheless, the aim of this study was to replicate and 
verify the data from Zeng et al. (2009) who used the same antibodies as what 
has been used in this study. 
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A simple method for improving the specificity of methyl-lysine histone 
antibodies has been suggested (Connor et al. 2010). This method involves pre-
incubation of the antibody with the peptide of the histone modification for 
which the antibody shows non-specificity (Connor et al. 2010). This clean-up 
procedure resulted in significant improvement in the specificity of the 
antibodies in ChIP (Connor et al. 2010). This method can be used on 
polyclonal antibodies prior to ChIP to purify the solution from any antibodies 
that show any cross-reactivity. 
5.3 ChIP-qPCR results 
Zeng et al. (2009) reported that there was a reduction in H3K9me3 histone 
modification in a region within the D4Z4 repeats (Q-PCR region) in FSHD 
patients. The results obtained from the ChIP-qPCR analysis in this study 
confirm that there is indeed a reduction in H3K9me3 occupancy at the Q-PCR 
region in FSHD patients. However, contradictory to Zeng et al. (2009), the 
reduction of H3K9me3 in FSHD patients was also observed at DXZ4 and other 
regions analysed (Figure 4.18). 
There was a difference in H3K9me3 histone modification occupancy between 
the two control cell lines (GM16352 and GM08729). This is not unexpected 
since there are numerous variations within the genome and consequently 
variation in the epigenome is inevitable. This demonstrates the importance of 
having more than one control cell line in epigenetic studies. This issue 
highlights a weakness in the ChIP-qPCR data from Zeng et al. (2009). The 
ChIP-qPCR data from Zeng et al. (2009) are shown as relative to a control. 
Our data shows that normalisation to different controls can result in different 
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conclusions (Figure 5.1). If the data is normalised to GM16352 control cell 
line, it can be concluded that there is about a 50% reduction in H3K9me3 
histone modification at the Q-PCR region in FSHD patients. Whereas, if the 
data is normalised to GM08729 control cell line, it can be concluded that there 
is a 70% reduction in H3K9me3 histone modification at the Q-PCR region, 
which is more similar to the data from Zeng et al. (2009). Therefore, it can be 
concluded that a larger number of control and FSHD cell lines is needed to 
validate these findings. A larger number of cell lines would allow for 
calculation of an average level of a specific histone modification at the region 
of interest in control cell lines, which could then be compared to individual 
FSHD cell lines or to an average of multiple FSHD cell lines. This would also 
allow for statistical analysis in order to determine whether there is a significant 
difference between the FSHD and control cell lines. 
The ChIP-qPCR analysis also indicated a reduction in H3K27me3 in FSHD 
patients amongst all the regions analysed (Figure 4.19). This is contradictory to 
the data from Zeng et al. (2009), where no difference in H3K27me3 at the Q-
PCR region between FSHD and controls was reported. Since the reduction of 
H3K27me3 histone modification was not exclusive to a specific region, it can 
be speculated that there is a global reduction in this histone modification in 
FSHD patients and the D4Z4 repeats are one of the many regions affected. In 
order to investigate this further, ChIP-qPCR analysis of a wider range of sites 
within the genome is required. Coupling of ChIP with microarray (ChIP-CHIP) 
and high throughput sequencing (ChIP-seq) would allow a more precise 
genome-wide analysis of the H3K27me3 histone modification in FSHD 
patients. 
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Figure 5.1 Normalisation to a control cell line.  
The ChIP-qPCR data was normalised to either GM16352 control cell line (top 
image) or to the GM08729 control cell line (bottom image). 
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5.4 Future work 
As discussed above, a larger number of control and patient cell lines is needed 
for statistical analysis and validation of the ChIP-qPCR data obtained so far. In 
addition, the use of Taq-Man probe instead of SYBR green would increase the 
specificity of the qPCR analysis. The probes could be designed using the 
sequence variants that differentiate between the D4Z4 repeats on 4q, 10q and 
other D4Z4-like sequences on other chromosomes. Haplotype-specific probes 
could also be designed using the sequence variants within the p13-E11 region 
to compare the ChIP-qPCR data at the proximal regions of the disease 
permissive and non-permissive alleles. 
Recently, a paper was published reporting the presence of two polymorphisms 
in the pLAM sequence of the disease permissive haplotypes that create a 
polyadenylation site for the distal DUX4 transcript (Lemmers et al. 2010). The 
pLAM region is immediately distal to the last repeat and is absent from the 
non-permissive 4qB haplotype. The polyadenylation site in the pLAM region is 
thought to stabilise the transcripts from the distal D4Z4 repeat (Dixit et al. 
2007; Snider et al. 2009). This, in combination with the chromatin relaxation at 
the D4Z4 repeats, may lead to increase in DUX4 transcript levels and therefore 
it is hypothesised that FSHD is caused by toxic gain of function of DUX4 
(Lemmers et al. 2010). It would be extremely interesting to study and compare 
the histone modification changes at the last repeat and the pLAM region 
between controls carrying the permissive haplotypes, FSHD2 patients and 
FSHD1 patients. However, it will be quite challenging to design primers and 
probes specific to the last repeat and the pLAM region, which consists of two 
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CG-rich LSau regions (similar to LSau within each repeat) and a 68bp region 
of Sau 3A repeats (van Geel et al. 2002). 
In conclusion, the ChIP-qPCR data from this project was in agreement with the 
data published by Zeng et al. (2009) on the reduction of H3K9me3 histone 
modification at the D4Z4 repeats in FSHD patients. However, contradictory to 
their data, the reduction of this histone modification was also observed on other 
regions analysed. A global reduction of H3K27me3 was also observed in 
FSHD patients. Further studies using a larger set of control and FSHD cell 
lines with more precise detection methods (ChIP-CHIP or ChIP-seq), coupled 
with DNA methylation studies, should lead to a deeper understanding of the 
change in the chromatin structure, especially at the distal region of the 4q 
allele, in FSHD patients. 
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